

National Guidelines on the Appropriate Clinical Use of Red Cell Concentrates in Pakistan

Usman Waheed¹, Samina Tufail Amanat², Dure Naz Jamal³, Muhammad Hanif Mengal⁴, Noore Saba⁵, Akhlaaq Wazeer⁶, Muhammad Tariq Masood Khan⁷, Shabnam Bashir⁸, Uzma Ata⁹, Huma Riaz¹⁰, Zahida Qasim⁶, Muhammad Rehan¹¹, Muhammad Bilal Ghafoor¹², on behalf of the Bring Brilliant Minds of Transfusion (BBMT) - Pakistan

¹ Department of Allied Health Sciences, Islamabad Medical and Dental College, Islamabad, Pakistan

² Saminat Amanat Laboratory and Medical Centre, Islamabad, Pakistan

³ Sindh Blood Transfusion Authority, Provincial Ministry of Health, Karachi, Sindh, Pakistan

⁴ Quetta Regional Blood Centre, Provincial Ministry of Health, Balochistan, Pakistan

⁵ Peshawar Regional Blood Centre, Provincial Ministry of Health, Khyber Pakhtunkhwa, Pakistan

⁶ Mirpur Regional Blood Centre, Divisional Headquarters Teaching Hospital, State Ministry of Health, AJK, Pakistan

⁷ Department of Haematology, Pak International Medical College, Peshawar, Khyber Pakhtunkhwa, Pakistan

⁸ Institute of Blood Transfusion Services, Lahore, Punjab, Pakistan

⁹ Regional Blood Centre, Dow University of Health Sciences, Karachi, Pakistan

¹⁰ Department of Pathology and Transfusion Medicine, Hayatabad Medical Complex, Peshawar, Pakistan

¹¹ Department of Burns and Reconstructive Surgery, Pakistan Institute of Medical Sciences, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan

¹² Department of Pathology, Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, Pakistan

Address of Correspondent

Noore Saba, MBBS, MPH, MPhil Haematology

Consultant Haematologist

Peshawar Regional Blood Centre

Provincial Ministry of Health,

Khyber Pakhtunkhwa, Pakistan

E: dr.nooresaba@gmail.com

Cite this editorial as: Waheed U, Amanat ST, Jamal DN, Mengal MH, Saba N, Wazeer A, et al. National Guidelines on the Appropriate Clinical Use of Red Cell Concentrates in Pakistan. Ann Pak Inst Med Sci. 2024; 20 (Suppl. 2): 885-908. doi: 10.48036/apims.v20iSuppl.2.1285.

“The best blood is the one that you have not transfused”

Blood transfusion is a critical component of modern healthcare. Human-derived therapeutic products, including blood, its labile components, and plasma-derived medicinal products, play a significant role in medical treatment.^{1,2} Ensuring availability and equitable access to safe and high-quality blood is essential for achieving universal health coverage.

The demand for blood is rising due to two primary factors: (i) advancements in the diagnosis and treatment of complex diseases, and (ii) the growing number of

aging populations with increased blood requirements. When used appropriately, blood transfusion can be lifesaving, but it may also pose risks such as acute or delayed transfusion reactions and the transmission of infectious agents, including HIV, hepatitis viruses, spirochetes, and malaria parasites.³

Ensuring an adequate, safe, and effective supply of blood and blood components requires attention to their clinical use. Achieving safety and clinical efficacy involves obtaining blood from healthy and regular donors and

conducting accurate, reliable, quality-controlled testing, and processing. This process demands substantial human and financial resources and involves a collaborative effort between blood transfusion services, prescribers, and administrative authorities to allocate sufficient resources for blood supply and its appropriate rational use.

Blood transfusion therapy relies on the availability of different blood components. The use of specific components, either separately or in combination, addresses the transfusion needs of most patients while minimizing risks. The clinical use of blood thus ensures that the right blood component is used for the right patient, at the right place, dose, time, and indication.⁴

Efficient utilization of blood and blood components is crucial to avoid its unnecessary use, as such practices can lead to shortages for those in real need while expose others to undue transfusion risks. Safety must be the priority for clinicians, patients, and their families. Blood should be used appropriately and only when clinically indicated, with clinicians prepared to manage any adverse events and hence, proper patient identification during sample collection and transfusion is essential.⁵

Red Cell Concentrates (RCC) or Packed Red Blood Cells (PRBC) transfusion is a life-saving procedure with primary objective of sustaining tissue and organ oxygenation in patients with massive bleeding or acute anaemia. RCCs for transfusion are routinely stored for up to 35 or 42 days, depending on the anticoagulant solution (CPDA-1 and SAGM).^{6,7} This time limit has been determined mainly by the recovery and the lifespan of the RBCs in the circulation of recipients.⁸⁻¹¹

Clinicians must discuss the benefits and risks of transfusion with patients and obtain informed consent. Measures to reduce adverse reactions should be implemented, including the use of modified components (e.g. leucoreduced cells) for patients requiring repeated transfusions.¹²

Alternatives to allogenic blood transfusion should also be considered, such as blood conservation techniques during surgery, autologous transfusion, or the use of pharmacological agents. Developing effective communication between blood providers and prescribers is vital to ensure: (i) that a sufficient and safe blood supply is accessible to all in need, and (ii) appropriate clinical use of blood and blood components.

Blood and its components play an essential role in modern healthcare. However, transfusion services

constantly face challenges related to safety, cost, and the availability of blood. Despite strict processes and procedures designed to ensure safe transfusion practices, the risk of complications remains. This highlights the importance of ensuring that transfusions are appropriate. The responsibility for safe, efficient, and effective blood transfusion lies with both transfusion services and the prescribers. The safety and effectiveness of a blood transfusion mainly depend on five key factors:

- A sufficient supply of safe blood and blood components, accessible at reasonable cost and adequate to meet the national and local needs.
- Safety of blood and blood components, with blood adequately tested for the absence of infectious pathogens and for blood group antigens and antibodies as appropriate and necessary.
- Appropriate processing and safe handling of blood monitored by key quality indicators.
- The appropriate clinical use of blood and blood components. This comprises the assessment of anaemia and haemostasis of the recipient, and the use of measures that can reduce the transfusion of unnecessary blood products.
- Evaluation of benefits and risks related to blood transfusion prior to transfusion.

Appropriate blood transfusion is defined as the administration of safe blood and blood components to treat a condition that causes significant morbidity or mortality and cannot be effectively prevented or managed by alternative methods. Proper use of blood helps minimize the potential risks associated with transfusions.¹³ Pertinence of transfusion now also comprises the use of the most appropriate blood components or derivative available when choices can be made, and in the correct dose, to meet the patient's specific need.² As if used appropriately, blood transfusion can save life and improve health. However, evidence from every region of the world indicates considerable variations in patterns of clinical blood use between different hospitals, diverse clinical specialties and even between different clinicians within the same team.⁴ This suggests that the use of blood and blood components is often not been optimized, behind lack of apt information and/or education regarding the subject matter.

Haemovigilance

In transfusion medicine, the concept of haemovigilance has emerged during the last three decades. Haemovigilance is a set of processes that brings the entire

vein to vein chain of blood transfusion under examination to avoid any untoward events from donor end to the recipient end and to document it thus maximizing the donor recruitment and retention and making the provision of blood transfusion more efficient and safer.^{14,15}

According to the International Haemovigilance Network (IHN), Haemovigilance is a set of surveillance procedures covering the entire transfusion chain, from the donation and processing of blood and its components to their provision and transfusion to patients and their follow-up. It includes monitoring, reporting, investigation, and analysis of adverse events related to the donation, processing, and transfusion of blood, and taking actions to prevent their occurrence or recurrence.¹⁶

Haemovigilance, at its core, is purely data record keeping and drawing conclusions from the results to correct any malfunction in the blood transfusion services. The data obtained also forms the basis for renovating systems, revising policies and strategies, refining standards, and practices all adding to the safety of the blood transfusion chain. Nearly four decades ago, i.e. in the 1980s, haemovigilance systems were triggered by the terrible experience with transfusion-transmitted HIV cases. The first reporting system of screening HIV as TTI was developed by France through a legislation in 1994.¹⁷ Soon after, many other European countries stepped forward and passed similar legislation in line with the EU (European Union) directives.

The haemovigilance is no longer limited to patients getting a blood transfusion (recipients) but covers entire vein to vein transfusion chain including, (i) collecting information on adverse events/reactions associated with blood collection (donor haemovigilance); (ii) monitoring the frequency of transfusion-transmitted infections in blood donors, monitoring the processing and testing of donated blood; and (iii) authenticating the transfusion of blood components to recipients and collecting information on adverse events/reactions associated with transfusion of blood and blood components (recipient haemovigilance).

The haemovigilance reporting can be 'hot' if the adverse events or reactions are immediately reported, or it can be 'cold' when the reporting is periodical, e.g. annual reports with data analysis and recommendations. Haemovigilance is also a critical element of quality control in a blood system, allowing remedial and preventive actions, and for the continuous advancement of the quality and safety of blood, blood components and

the transfusion process.¹⁸ Therefore, haemovigilance forms an essential part of quality management in blood transfusion services. It can be compared with the 'check' step of the PDCA cycle (plan – do – check – act), which is a four-step management technique applicable to the control and perpetual improvement of processes. The characteristics of a haemovigilance system include:

- Confidentiality
- Professionally owned
- Not punitive (no punishment)
- Voluntary/mandatory
- Sufficient detail to make effective recommendations
- Focus on improved safety and outcomes

The haemovigilance can be successfully implemented and maximum benefit obtained if the data analysis and resulting conclusions are mutually shared with the stakeholders including hospital transfusion services, blood centre, clinical faculty, quality department, infection control department, nursing department, hospital transfusion committee (HTC), and blood transfusion authority (BTA).¹⁹ The ultimate aim of a strong haemovigilance network is to identify the problem areas as well as successful interventions and linking the data globally for a more coherent approach in the blood transfusion services. The basic requirements of a haemovigilance system include (but not limited to):

- Awareness of the clinical staff regarding the need to monitor adverse reaction
- System for reporting incidents
- Guidelines, training, and refreshers
- Hospital transfusion committees (HTC)
- Regular analysis of transfusion practices
- Ensure implementation of appropriate preventive measures
- Traceability of all products from donor to patient
- The system for the recall implicated donations/products/donors
- Robust no blame approach - participants feel free to report incidents without fear
- Ongoing assurance that the focus of the programmes is only on the improvement of patient care

The haemovigilance system can be 'centralized' or 'decentralized'. For a 'centralized' haemovigilance model, which is taken as the best method internationally, there is a central haemovigilance headquarter that collects data from all the blood centres and hospitals responsible for managing the adverse event(s) in blood donors or recipients. Reports of the data analysis with feedback and

recommendations are made available to all stakeholders nationally. While in the ‘decentralized’ haemovigilance model, there is no central body to gather data instead it may be organized at a lower level, e.g. province-wide or at state-level. However, it is pertinent to mention here that regardless of the model adopted by a country, it must be simple, confidential, and quick.²⁰ In addition to ‘donor and process haemovigilance’, a key aspect of haemovigilance is the ‘patient or recipient haemovigilance’ where transfusion reactions and adverse events in recipients are investigated by the clinical team and reviewed by HTC.²¹

In Pakistan, the ‘National Guidelines for Quality Control in Transfusion Medicine’ were formulated in 2007 and later revised in 2017 and 2020 by the Safe Blood Transfusion Programme of Pakistan’s National Health Ministry to ensure the maximum safety of all procedures for donors, recipients, and staff involved in transfusion services. This document includes a chapter on haemovigilance with a basic introduction and key forms to be filled in for reporting an adverse event both in the donors and the recipients.²² We strongly encourage our readers to fully utilize this document when implementing haemovigilance in blood centers and hospital settings.

The establishment of an effective haemovigilance system is a dire need of Pakistan because substantial risks with regards to blood donation and transfusion of blood and blood components exist and cannot be denied. Haemovigilance can help quantify these risks and qualify them, leading to changes and improvement of quality and safety all along the blood chain, to the benefit of donors, patients, and staff.²³

Physiology of Red Blood Cells

The normal daily production of red blood cells (RBCs) in a healthy adult is about 0.25 mL/kg and the average lifespan of the cells is about 120 days, whereas that of transfused RBCs is about 50-60 days and can be significantly shorter in the presence of factors reducing their survival.²⁴

The storage of RCCs leads to a series of metabolic, biochemical and molecular changes, defined globally as the storage lesion; the extent of these changes is related to the duration of the period of storage.²⁵⁻²⁷ Depletion of 2,3-diphosphoglycerate (2,3-DPG) occurs within a few days of the start of storage and is completed within 1 or 2 weeks. This alteration is reversible: 50% of the 2,3-DPG is restored by 8 hours after starting the transfusion, while

24 - 72 hours are necessary for complete recovery. This can be clinically relevant in patients who require massive transfusions.²⁸⁻³⁰

Informed Consent Before a Transfusion

To uphold the principle of autonomy or self-determination, it is essential to obtain informed consent from the recipient or their relative prior to transfusion. The key elements of informed consent include:

- Informing the patient about the necessity of the transfusion, the associated risks of both undergoing and forgoing the procedure, and any available alternatives.
- Obtaining the patient's written consent in the language they best understand after providing the necessary information. Ensure that the consent form is signed by the patient.
- For minors under the age of 18, unconscious patients, or those individuals’ incapable of making decisions, consent must be provided by a parent or the next of kin.

Guidelines for Obtaining Informed Consent

Obtaining informed consent before a blood transfusion involves specific considerations to ensure that patients (or representative) fully understand the process, its risks, and benefits. Using non-technical terms to describe the transfusion and its implications is recommended and then asking the patient to repeat or explain back the information back in their own words to confirm comprehension. Key steps include:

- Allowing the patient to ask questions and address their concerns.
- Documenting the obtained consent by completing a transfusion consent form.
- Clearly recording the reason for the transfusion in the patient's medical chart.
- Whenever feasible, discuss consent for the transfusion early enough to consider alternative blood management strategies.
- If the patient refuses the transfusion, documenting this refusal, including the patient's signature and a witness.
- While respecting the patient’s decision, ensuring they are informed about all available alternative strategies to blood transfusion and also being offered.

Pre-transfusion Sample Collection

Pre-transfusion testing is essential to prevent the transfusion of incompatible donor red cells, which could lead to an immune-mediated haemolytic transfusion reaction. It is important that blood transfusion requests include sufficient information to accurately identify the recipient and avoid potential errors. For sending blood samples to the blood bank with requisition form, the following should be considered.^{31,32}

- If one unit of blood is required, a 3-5 mL blood sample in an EDTA (ethylene diamine tetraacetic acid) vial should be submitted.
- For each additional unit, an extra 1 mL of blood in a plain vial should be sent.
- For infants under four months of age, send EDTA samples from both the mother and the infant: 5-cc of clotted blood from the mother and 1-cc of EDTA blood from the infant. For repeated transfusions, only a sample from the mother is needed.
- For double volume exchange transfusion (DVET), submit a 3 mL sample from the mother along with a neonatal EDTA sample.
- Blood samples for crossmatching should be collected no more than three days before the transfusion.
- When requesting plasma components or platelet concentrate, if the blood group has not been previously checked, include a blood sample with the request.
- In true emergency situations, telephone requests are acceptable, but they must be followed by a written request.
- For investigations related to transfusion reactions, send a 5-cc post-transfusion clotted blood sample, an EDTA sample, urine sample to evaluate haematuria, a completed adverse reaction notification form along with any remaining implicated blood unit.
- Deliver the sample and the requisition form to the blood bank.
- The blood bank laboratory will perform antibody screening and compatibility tests. If issues arise during crossmatching, the blood bank may need additional time to locate a compatible blood unit.

Considerations Before Prescribing Blood³³

- Can you minimize the patient's need for transfusion?
- Are there specific clinical or laboratory indications for blood transfusion?

- Is there any other alternative treatment you could consider before giving blood - such as IV fluids and any drugs that achieve haemostasis?
- Are you likely to achieve any improvement in the patient's clinical condition?
- What other options are there if blood for transfusion is not available in time?
- Will a trained person monitor this patient during transfusion and respond immediately if any acute transfusion reactions occur?
- Have you recorded the decision and reasons for transfusion on the patient's chart and the blood request form?
- Do the benefits outweigh the risks of this transfusion?
- Will you use blood transfusion for yourself or your dear one in this condition?

Receipt of Blood and Instructions for Administration^{34,35}

- Blood for transfusion should be collected just before the transfusion begins. Use a clean, cool box to transport the blood bag from the blood bank to the hospital/ ICU/OT/ward.
- Blood or blood components should never be stored in unmonitored domestic refrigerators, as proper storage conditions cannot be guaranteed.
- Inspect the blood bag for signs of haemolysis, discolouration, clots, turbidity, and leaks. When the bag reaches the hospital, the distinct separation between red cells and plasma may not be visible, but a red colour with a metallic sheen indicates haemolysis.
- A completely haemolyzed RCC unit can be identified by a colour change from red to black.
- Saline-washed red cells prepared using an open system should be used within six hours.
- Administer blood within 30 minutes of issue from the blood bank. If there is a delay, return the blood unit to the blood bank within 30 minutes, ensuring the blood bag is not damaged. Avoid non-medical reasons for delays in starting a transfusion.
- Except in emergencies, blood transfusions should be avoided at night.
- Use 18G needles for routine transfusions and 23G scalp vein sets for paediatric transfusions.
- Administer blood or blood components using a disposable transfusion set with a filter.
- Record the patient's blood pressure, pulse rate, and temperature before, during, and after the transfusion.

- The infusion rate should be adjusted based on the patient's condition. It is recommended to start the infusion slowly for the first 15 minutes, at approximately 100 mL/hour or 1-6 mL/minute (24 drops). If no adverse reactions occur after 15 minutes, the rate can be increased. RCCs should typically be infused within two hours, while whole blood transfusions should be completed within four hours. Rapid transfusion may be necessary for patients with congestive heart failure.
- Observe the patient for any signs of transfusion related adverse events, such as febrile reactions, haematuria, oliguria, or hypotension.
- In the event of a transfusion reaction, stop the blood transfusion immediately and inform the attending physician and the issuing blood bank.
- In case of mild reactions, the transfusion may be temporarily paused and resumed at a slower rate after evaluating the patient's condition.
- If signs and symptoms are severe, then send the remaining blood unit or blood component, along with a 5-cc post-transfusion clotted blood sample, an EDTA sample, urine sample and a completed adverse transfusion reaction notification form to the blood bank for further investigation.
- If the transfusion is completed without any complications, document the time the transfusion finished and the exact volume of blood transfused.

Indications

The following clinical parameters are to be evaluated when considering a transfusion:³⁶⁻³⁹

- Age and gender
- Signs and symptoms of anaemia
- Speed and volume of blood loss
- Cardiac function
- Lung function
- Ischaemic heart disease
- Pharmacological treatments

General Indications for Surgical / Gynaecological Patients⁴⁰

The general indications for surgical patients are subdivided into pre-operative, per-operative and post-operative indications.

Pre-Operative Indications

Pre-operative screening should be done with history, physical examination, blood CP, and alloantibody

screening. Antiplatelet drugs should be stopped seven days before planned surgeries. Reversible causes of anaemia should be treated before surgery to raise the level of haemoglobin (Hb) to 10 g/dL. All surgeries can be performed on all the patients with Hb $\geq$ 10 g/dL.⁴¹⁻⁴⁴ The pre-operative indications for transfusions are, (i) if Hb is $<$ 8g/dL, transfusion is required,⁴⁵⁻⁴⁸ and (ii) in the presence of heart or lung disease, maintain Hb of $>$ 8g/dL.⁴⁹

Per-operative Indications

The amount of blood loss and oxygen saturation drives the decision to transfuse. About 10% of blood volume may be taken as allowable blood loss, that can safely be replaced with crystalloids.⁵⁰ Blood loss of up to 750 mL (15% blood volume) can be replaced by crystalloids and requires no transfusion unless blood loss is superimposed on preexisting anaemia, or the patient is unable to compensate for it due to preexisting cardiovascular or pulmonary compromise.^{51,52} Blood loss of 800-1500 mL (15-30% blood volume) in the presence of pre-existing anaemia, cardiovascular or lung disease should also be replaced first by crystalloids unless blood loss is superimposed on preexisting anaemia, or the patient is unable to compensate for it due to preexisting cardiovascular or pulmonary compromise. In case of blood loss between 1,500-2,000 mL (30-40% blood volume), replace with crystalloids, however, blood transfusion is required in most of the cases. A blood loss of more than 2,000 ml ($>$ 40% blood volume) requires confirmed blood transfusion, and this also holds true for post-partum haemorrhage.⁵³⁻⁵⁶ Medical conditions where the amount of blood lost cannot be assessed, vital signs guide the decision to transfuse.

Post-operative Indications

Post-operative blood transfusions are often indicated to manage or prevent complications arising from significant blood loss or reduced oxygen-carrying capacity. Some degree of haemodilution can be expected in patients who have lost blood during a procedure. For this reason, an Hb level performed postoperatively is very likely to be lower than the preoperative level. This alone is not an indication for a blood transfusion, and the decision to transfuse should only be made following careful assessment of the patient. The objective is to maintain a Hb between 8-10 g/dL.⁵⁸ Consideration should be given to the general condition of the patient and to coexisting cardiopulmonary disease, signs of inadequate tissue oxygenation, and continued blood loss.⁵⁹

General Indications

Reversible (treatable) Anaemias

The first line therapy is treatment with hematinic, blood transfusion should be kept as a last resort. In the presence of iron deficiency anaemia, megaloblastic and reversible haemolytic anaemia, the decision to transfuse should rest on patient's clinical condition. Minimum Hb of 6 g/dL is acceptable for well compensated chronically anaemic patients.^{60,61} If a heart or lung disease is present or the patient is more than 65 years old, maintain a haemoglobin of ≥ 8 g/dL.⁶² For pregnant females, the following indications apply for transfusion of RCCs:^{63,64}

- Hb of 5.0 g/dL or below, even without clinical signs of cardiac failure or hypoxia⁶⁵
- Hb between 5.0 and 7.0 g/dL and in the presence of the following conditions:
 - established or incipient cardiac failure or clinical evidence of hypoxia
 - pneumonia or any other serious bacterial infection
 - malaria
 - pre-existing heart disease, not causally related to the anaemia⁶⁶

Irreversible Anaemias

Congenital

Thalassaemia Major: Transfuse when the Hb is < 9 g/dL.⁶⁷⁻⁷¹

Sickle Cell Disease: Do not transfuse till the Hb is < 7 g/dL, maintain Hb between 7-10 g/dL. If surgery is planned, maintain Hb between 10-12 g/dL, HbS is to be reduced to less than 30%.⁷²⁻⁷⁶

Other Congenital Anaemias: In cases of pure red cell aplasia, congenital dyserythropoietic anaemias, haemoglobinopathies, enzymopathies and membrane disorders, the decision to transfuse should rest on patient's clinical condition.^{77,78}

Acquired

Chronic Renal Failure: Maintain haematocrit (HCT) at $\geq 30\%$.^{79,80}

Myelodysplastic Syndrome, Aplastic Anaemia: The decision to transfuse should rest on patient's clinical condition.^{81,82}

Chemotherapy, Neoplasia: Maintain Hb of ≥ 8 g/dL.^{83,84}

Massive Transfusion

Experimental evidence suggests that HCT as high as 35% may be required to sustain haemostasis in this context.^{85,86}

Burns

Anaemia and hypoproteinaemia commonly develop following extensive burns. These can be minimized by ensuring that burns patients receive a high-protein, high-calorie diet. Vitamin supplements and hematinic should also be administered. Blood transfusion should only be considered when there are signs indicating inadequate oxygen delivery.⁸⁷⁻⁹⁰

Indications for Modified Red Cell Concentrates

Leucodepleted RCCs

Used mainly for the prevention of febrile non-haemolytic transfusion reactions (FNHTR) caused by the presence of antibodies to white blood cells, other indications are:⁹¹⁻⁹⁴

- patients with recurrent FNHTR
- patients who need prolonged transfusion support
- reduction of the incidence of CMV infections in:⁹⁵⁻⁹⁷
 - CMV-negative patients with congenital or acquired immunodeficiency⁹⁸
 - CMV-negative recipients of a BMT (bone marrow transplant) from a Cytomegalovirus (CMV) negative donor^{99,100}
- reduction of the risk of rejection in candidates for haematopoietic stem cell transplantation¹⁰¹
- prevention of refractoriness to platelet transfusion
- intrauterine transfusion
- preterm babies
- neonates, and paediatric patients up to one year old, if there is a prior history of intrauterine transfusion¹⁰²⁻¹⁰⁵

Irradiated RCCs¹⁰⁶

Irradiation, at the dose of 25 Gy (and not > 50 Gy), is currently the only method available for preventing transfusion-related graft-versus-host disease (GvHD). The only unfavourable effect of irradiating RCCs is hyperkalaemia, due to the accelerated release of potassium from the RBCs. This effect is of little significance in adults but can cause serious problems in the case of intrauterine transfusions or exchange transfusions.¹⁰⁷⁻¹⁰⁹ The main indications are:¹¹⁰⁻¹¹³

- intrauterine transfusions
- immunosuppressive agents therapy
- transfusion in neonates with a birth weight of $\leq 1,500$ g and/or gestational age ≤ 30 weeks
- congenital cellular immunodeficiency
- transplant candidates
- relatives as blood donors, who are also future potential BMT donors
- chemotherapy with purine analogs

Washed RCCs¹¹⁴⁻¹¹⁷

- indicated in patients with IgA deficiency
- prevention of allergic reactions not sensitive to antihistamine drugs
- post-transfusion febrile reactions, present even when leucodepleted RCCs are used
- paroxysmal nocturnal haemoglobinuria

Frozen RCCs

These are indicated in patients with complex immunohaematological profiles in the absence of compatible donors, e.g.:¹¹⁸

- rare blood groups
- multiple alloantibodies
- IgA deficiency

Blood Warming

In elective transfusions where a unit of blood is administered over 2-4 hours, there is no need to warm the blood. Routine transfusions do not require blood warming, as maintaining the patient's body temperature is more crucial than warming the infused blood, because blood gradually attains body temperature as it flows drop by drop during the transfusion. It is a common misconception that non-warmed blood infusions cause febrile reactions, additionally, warming blood can lead to increased red cell metabolism, a reduction in 2,3-DPG levels, and an elevated risk of bacterial growth.¹¹⁹⁻¹²¹

Warming of blood is useful when rapid transfusion of components is required, especially in trauma¹²² or surgery settings because infusion of cold blood/components can cause hypothermia and cardiac complications, increasing morbidity and mortality for the patient.¹²³ Transfusion at rapid rates (100 mL/min) for 30 minutes of refrigerated blood can lower the temperature of the sino-atrial node to below 30°C and cause ventricular arrhythmias and cardiac arrest. Blood should only be warmed in a blood warmer, which should have a visible thermometer, an

audible warning alarm and be properly maintained. Blood should not be warmed by placing it in a microwave, on a heat source, or in unmonitored hot water or by using other devices not specifically approved for blood warming.¹²⁴ Warmed blood is mostly required in:^{125,126}

- large volume rapid transfusions:
 - adults: greater than 50 mL/kg/hour
 - children: greater than 15 mL/kg/hour
- transfusions to neonates
- exchange transfusion in infants
- patients with clinically significant cold agglutinins

Dosage of RCC

Calculate the number of units by the increment in Hb needed. In general, apart from cases of acute haemorrhage, transfusion of only one unit of red cell concentrate/day is recommended.¹²⁷ The dosage needs to be modified on an individual basis to prevent transfusion associated circulatory overload (TACO).¹²⁸⁻¹³⁰

Adults

In adults, the dose is 10-20 mL/kg body weight. In the presence of cardiac failure, this is reduced to 3-5 mL/kg. The rate of transfusion is 3-5 mL/kg/hour. As a rough estimate, one unit of RCC increases Hb by 1 g/dL in adults.

Children

In children, the transfusion of 10-20 mL/kg body weight increases the Hb concentration by about 1 g/dL.^{131,132}

Neonates

The generally recommended dose of RCCs is 5-20 mL/kg body weight.¹³³ In case of exchange transfusion in neonates, for a term infant the dose is 80-160 mL/kg, whereas for a preterm infant it is from 100-200 mL/kg body weight.^{134,135}

Transfusion Yield

As a rough guide, in the adults, one unit of RCC increases the Hb concentration by 1 g/dL and the HCT by about 3%.¹³⁶⁻¹⁴⁰ In children, the transfusion of 5 mL/kg increases the Hb concentration by about 1 g/dL.^{141,142} In the case of a lower-than-expected transfusion yield, conditions causing the loss, sequestration or destruction of red cells should be looked for. Such conditions include:

- Occult bleeding

- Repeated blood sampling (particularly in children)
- Fever
- Hypersplenism
- Primary and secondary immunological causes
- Mechanical or other types of haemolysis

Rate of Transfusion

For the first 15 minutes of a transfusion, administer blood at a slow rate of approximately 25-50 mL. If no adverse reaction occurs, the rate can be increased based on the recipient's haemodynamic status. All blood transfusions should be completed within a 4-hour time frame. In a haemodynamically stable patient, the transfusion can typically be completed within two hours. However, for a haemodynamically unstable patient, the process may extend for up to four hours.^{143,144} If the recipient's medical condition necessitates a longer transfusion period, request the blood bank to divide the unit into aliquots and transfuse each aliquot over four hours to mitigate the risk of bacterial contamination. For elderly patients and those with congestive heart failure, adjust the rate and volume of the transfusion to avoid cardiac overload, and consider the use of diuretics as needed.

When rapid transfusion is required, avoid using a blood pressure cuff for external pressure on the blood bag, as it may cause barotrauma and haemolysis. If a cuff is used in an emergency, keep the pressure between 100-150 mmHg. The preferred method for regulating and monitoring the rate is a commercially available in-line infusion pump, when available.

Blood Group Compatibility

The criteria for blood-group compatibility for the transfusion of RCC are reported in Table 1:

Table 1: ABO phenotype of RCC units to transfuse

ABO phenotype of the recipient	ABO phenotype of units to transfuse (in order of preference)
O	O
A	A, O
B	B, O
AB	AB, A, B, O

Addition of Drugs and Medications to Blood Bag / Blood Set

Except for normal saline, no drugs should be added to a blood bag. Use only 0.9% sodium chloride injection to dilute RCCs and reduce viscosity. If saline needs to be added, this should preferably be done in the blood bank.

Avoid using an IV line that has been used for any intravenous solution other than normal saline or 5% albumin for blood transfusion. Do not use 5% dextrose or Ringer Lactate for diluting RCCs, as these solutions cause red cell haemolysis. The simultaneous administration of 5% dextrose leads to haemolysis, while Ringer Lactate causes blood clotting in the tubing.¹⁴⁵ Adding drugs to blood bags can change the pH and ionic composition, which may lead to reduced drug effectiveness and a higher risk of bacterial contamination. In the event of a reaction, identifying the exact cause becomes challenging, making it difficult to discern whether the reaction was due to the blood itself or the added substances.

Documentation

Documentation of every step is a legal requirement as per blood safety acts promulgated in all confederating units. All documentation should be kept confidential. The following information should be recorded to prove appropriate use of blood:

- reason for transfusion
- tests done to decide regarding need for transfusion
- screening tests done on blood before use
- number of units transfused and observations during transfusion
- patient's health before and after transfusion
- tests done to record post transfusion improvement

Fresh Blood

Blood collected within the last 24 hours is often referred to as "fresh" as it contains all blood components.¹⁴⁶ However, clinicians are advised not to prescribe fresh blood for the following reasons:^{147,148}

Testing Limitations: Providing blood less than 24 hours old is impractical if thorough and reliable testing for transfusion-transmissible infections is to be conducted.

Component-Specific Needs: The demand for fresh whole blood as a source of coagulation factors, platelets, and white blood cells is unwarranted, as specific components can be administered individually.

Modern Practice: In many countries where blood component therapy is available, the use of fresh blood has become obsolete, with only the specific blood component needed for treatment being transfused.¹⁴⁹

Efficacy for Anaemia: There is no added benefit to using fresh blood over stored blood for correcting anaemia.

Safety of Stored Blood: Many infectious agents, such as spirochetes (causing syphilis), malarial parasites, and bacteria, do not survive storage temperatures after a few days, making stored blood safer.

Resource Management: The unjustified use of freshly collected blood can lead to the unnecessary wastage of other units due to expiration, making it preferable to follow the first-in, first-out (FIFO) policy.^{150,151} The use of whole blood is discouraged as it can deplete the supply of blood components. Transfusing components that are not needed increases the risk to the patient and is less efficient in resource management.

Special Cases

Newborns: Blood less than five days old is recommended for exchange transfusions to prevent hyperkalemia and to provide red cells with adequate 2,3-DPG content.

Hepato-Renal Patients: Blood less than 10 days old is suitable for patients with hepatic or renal issues to avoid complications from storage-related metabolites such as potassium, ammonia, and hemolysis.

Multi-Transfused Patients: Patients who require frequent transfusions should receive blood that is less than 10 days old to minimize the need for repeated transfusions.

General Use: For all other cases, blood up to its expiration date is effective for increasing haemoglobin levels.

Shelf life

The shelf life of red cell concentrates is 35 days in CPD A-1 anticoagulant. It is increased to 42 days with the addition of an additive solution (e.g. SAGM).^{152,153} When the RCCs are washed with saline they should be used immediately. If storage is unavoidable, it must not exceed 24 hours of washing.¹⁵⁴ The shelf life of irradiated red cell concentrates is reduced to 14 days from the day of

irradiation, the maximum shelf life is 28 days. In cases of intrauterine transfusions, exchange transfusions and transfusions in neonates with a birth weight of $\leq 1,500$ g and/or gestational age ≤ 30 weeks, irradiated blood must be transfused within 48 hours of irradiation to prevent hyperkalaemia.^{155,156} Frozen red cells, if stored at -60 to -80 °C, can be stored for up to 10 years.^{157,158}

Duration

The blood must be transfused immediately without undue delays, to prevent mortality and morbidity. Transfusion can be administered faster in individuals with acute blood loss or slower/in smaller aliquots in persons with congestive heart failure. The transfusion in all cases must be completed within four hours of issuance of blood. In addition, the following must be borne in mind:¹⁵⁹⁻¹⁶²

- Do not keep the blood bag in ice
- Do not let the blood bag fold
- Do not press the blood bag to expedite transfusion
- Do not add any medication to the blood bag
- Do not transfuse if there is any fault, damage or leakage in the container
- Do not cover the blood with a towel for warming
- Warming of blood bags is only required in cases of transfusion at a rate of > 100 mL/kg/hour. The temperature of blood warmer should be at 37°C. If blood warmers are not available, then blood can be warmed in a water bath. The blood bag should, however, not come in direct contact with the water bath and be placed inside a tubing.¹⁶³
- Do not give blood transfusion through the saline I/V line^{164,165}

Common Misuses of Blood¹⁶⁶⁻¹⁶⁸

- Anaemia with Hb above 10 g/dL (in the absence of specific risk factors related to the patient's clinical characteristics)
- To replace hematinics (iron, vitamin B₁₂, folates)
- For re-constituent purposes
- To accelerate the healing of wounds
- To expand circulatory volume

Adverse Transfusion Reactions

Adverse blood transfusion reactions are described as an unfavourable response by the body to blood or blood components during or after a transfusion. These reactions can range from mild to severe and various frameworks

have been developed (e.g., International Haemovigilance Network [IHN] / International Society of Blood Transfusion [ISBT], Serious Hazards of Transfusion [SHOT], Transfusion and Transplantation Reactions in Patients [TRIP] data or National Healthcare Safety Network [NHSN]), that serve as excellent resources for background data and structured definitions on adverse transfusion reactions.¹⁶⁹ Four terminologies used are:

- *Adverse event* is an undesirable and unintended occurrence before, during or after transfusion of blood. It may be the result of an error, or an incident and it may or not result in a adverse reaction.^{170,171}
- *Incident* is a case where the patient is transfused with a blood component which did not meet all the requirements for a suitable transfusion for that patient, or that was intended for another patient. It thus comprises transfusion errors and deviations from SOPs that have led to mistransfusions. It may or may not lead to an adverse reaction.
- *Near miss* is an error or deviation from standard procedures or policies that is discovered before the start of the transfusion and that could have led to a wrongful transfusion or to a reaction in a patient / recipient.

Table 2: Signs and Symptoms of Adverse Transfusion Reactions (ATRs)^{169,204}

Sign/Symptom	Type of Reaction	Comment
Fever (temperature of $\geq 38^{\circ}\text{C}$ AND rise of $1\text{-}2^{\circ}\text{C}$ from baseline)	FNHTR, AHTR, TRALI (respiratory symptoms), and bacterial contamination, can be unrelated to blood transfusion	Can co-exist with other signs such as chills, rigors, myalgia, nausea or vomiting, dyspnoea, hypotension (≥ 30 mmHg below the baseline) and tachycardia (HR > 40 bpm above the baseline)
Urticaria, hives, pruritus	Allergic transfusion reaction, anaphylaxis	Can be mild and localized or more severe with generalized urticaria
Angioedema	Allergic transfusion reaction	May be preceded by tingling around the face and lips
Dyspnoea or hypoxia	TRALI, TACO, TAD, Severe Allergic transfusion reaction,	Severe dyspnoea without shock may occur in TRALI or TACO. TAD is a diagnosis of exclusion, and patients should be assessed for other causes of dyspnoea before making diagnosis
Stridor, bronchospasm	Allergic/anaphylaxis	
Pulmonary oedema	TACO, TRALI	
Hypotension (fall in systolic &/or diastolic BP by greater than 30 mmHg AND systolic blood pressure of 80 mm or less)	AHTR, severe allergic reaction, anaphylaxis, bacterial contamination, TRALI, Hypotensive reaction (Bradykinin mediated hypotension), can be unrelated to transfusion	Patients on ACE inhibitors are at risk. Risk is higher with bedside leukofiltration. Isolated hypotensive reactions are a diagnosis of exclusion, and occur within an hour of transfusion, in the absence of allergic or anaphylactic symptoms. These reactions usually require no/minor intervention.
Pain	FNHTR (generalized aches), AHTR (pain at the infusion site, abdomen, chest, loins), Anaphylactic reaction (chest pain)	

Severe anxiety or 'feeling of impending doom'	AHTR, bacterial contamination	Mild anxiety is common in patients on transfusions, especially for the first time. However, patients should be assessed for any transfusion reaction if anxiety develops.
Bleeding diathesis with acute onset	DIC can be associated with AHTR, bacterial contamination or massive transfusion	

*This list can be used as a guide and may not be inclusive. DIC: Disseminated Intravascular Coagulation, FNHTR: Febrile Non-Haemolytic Transfusion Reaction, AHTR: Acute Haemolytic Transfusion Reaction, TRALI: Transfusion Related Acute Lung Injury, TACO: Transfusion Associated Circulatory Overload, TAD: Transfusion Associated Dyspnoea

- *Adverse reaction* is an undesirable response or effect in a patient temporally associated with the administration of blood or blood components. It may, but need not, be the result of an incident.¹⁷²

Immediate Immunological Mechanisms¹⁷³⁻¹⁷⁵

- Acute haemolytic reactions^{176,177}
- Febrile non-haemolytic transfusion reactions (FNHTR)¹⁷⁸⁻¹⁸⁰
- Allergic reactions (anaphylaxis, urticaria)¹⁸¹
- Acute non-cardiogenic pulmonary oedema (transfusion-related acute lung injury - TRALI)^{182,183}

Delayed Immunological Mechanisms

- Delayed haemolytic reactions¹⁸⁴⁻¹⁸⁶
- Graft-versus-host disease (GVHD)¹⁸⁷⁻¹⁸⁸
- Post-transfusion purpura¹⁸⁹
- Alloimmunisation¹⁹⁰⁻¹⁹²

Immediate Non-immunological Mechanisms

- Reaction to bacterial contamination¹⁹³⁻¹⁹⁷
- Circulatory overload (TACO)^{198,199}
- Non-immunological haemolysis

Delayed Non-immunological Mechanisms

- Iron overload²⁰⁰⁻²⁰³

Post-transfusion Infections (e.g.)

- HBV, HCV, HIV
- Treponema pallidum
- Malarial Parasite

Special Clinical Situations

This section includes special clinical situations which are relevant only to the health facilities having the suitable infrastructure and provision of services.

Transfusion Support for Haemoglobinopathies

The transfusion support for haemoglobinopathies should ideally be:²⁰⁵⁻²⁰⁹

- Leukocyte depleted
- Preceded by an extended red cell phenotype
- ABO compatible
- Be matched for Rh and K antigens
- Be tested for HbS
- Preferably irradiated
- Not be from relatives who are potential bone marrow transplant donors

Transfusion of RCCs in BMT Patients

The need for RCC transfusions in BMT recipients varies greatly from patient to patient. All the patients who are candidates for BMT must be transfused only with leukocyte-depleted RCCs that are preferably of the same group and phenotype.²¹⁰⁻²¹³ Blood components filtered with the latest generation filters, able to reduce the leukocyte content by 99.9%, are a valid alternative to cytomegalovirus negative blood components.²¹⁴⁻²¹⁶ Transfusion support is required till engraftment is complete or longer if pure red cell aplasia or delayed haemolytic transfusion occurs, with an aim of always maintaining $\geq 8\text{g/dL}$ Hb. CMV negative blood components are required only for CMV negative patients.

Transfusion of RCCs in Infants

Less than 4 Months of Age

Reverse grouping is not required for infants less than four months of age.²¹⁷ The RCCs should preferably be:

- Leukocyte-depleted, of the same group and phenotype
- CMV-negative
- Irradiated

The thresholds for transfusion are as follows:

- Hb $<13\text{ g/dL}$ in first 24 hours of life²¹⁸
- Cyanotic heart disease, Hb $<13\text{ g/dL}$ ²¹⁹
- Clinical manifestations of anaemia (e.g., apnea, tachycardia, poor weight gain), Hb $<10\text{ g/dL}$

- Acute blood loss and not responsive to other forms of therapy
- Late anaemia, stable patient Hb < 7 g/dL
- Hypoxia or on ECMO, ECLS Hb < 12 g/dL
- Surgery with Hb ≤ 10 g/dl
- Clinical shock or severe decrease in BP, Hb < 10 g/dL

More than 4 Months of Age

For infants more than four months of age, the indications for transfusion are as follows:²²⁰⁻²²²

- Acute blood loss >15% of blood volume, or anticipation thereof, or hypovolemia not responsive to other forms of therapy
- Hb < 8g/dL in peri-operative period
- Postoperatively with signs of anaemia Hb < 10 g/dL
- Severe cardiopulmonary disease, Hb < 13 g/dL
- Patients receiving chemotherapy or irradiation, or patients with chronic anaemia not responsive to medical therapy, Hb < 7 g/dL (symptomatic patients may be transfused at a higher haemoglobin level)
- Clinical shock or severe decrease in BP, Hb < 10g/dL

Transfusion of RCCs in Neonates

In the case of neonates, units of smaller volume (pedipacks) should be used (25-100 mL) to prevent multiple donor exposure. The RCC should be:²²³

- Leucodepleted, irradiated, and CMV negative

Exchange Transfusion

Neonates

The indications for exchange transfusion²²⁴⁻²²⁷ in neonates are severe anaemia, heart failure, and hyperbilirubinaemia usually caused by HDN.

Sickle Cell Anaemia

The indications for exchange transfusion in sickle cell anaemia are vaso-occlusive crisis, acute chest syndrome, and priapism.²²⁸

Malarial Parasite

Exchange transfusion is required when infestation with *Plasmodium falciparum* is >5%.^{229,230}

Intrauterine Transfusions (IUT)

RCC preparations for IUT should be group O or ABO identical, and RhD negative, K-negative.^{231,232} If the mother is negative for allo-antibodies and the blood

group of the mother and the baby are the same, maternal transfusion can be given. If the blood group of the baby is not known, O-negative blood should be given.

Autologous RCC Transfusions

The indications for autologous RCC transfusions are the absence of compatible blood donors, e.g., rare blood groups, multiple alloantibodies, IgA deficiency, haptoglobin, C1 esterase inhibitors deficiency.²³³ Various techniques for preparing autologous RCCs are available globally. These are:²³⁴⁻²³⁶

- Blood collected and stored prior to an anticipated surgical or other need (pre-deposit)
- Blood salvaged intra- and post-operatively from surgical wounds and from cardiovascular bypass and extracorporeal membrane oxygenation (ECMO) circuits
- Haemodilution technique where blood is collected perioperatively, after the patient is anaesthetized and simultaneous replacement intravenous fluid is given.

Quality Control of RCCs

Ensuring a safe and efficacious supply of blood and blood components requires applying the principle of quality assurance to all aspects of components collection, preparation, testing, storage and transport. All QC procedures provided here are according to the National Guidelines for Quality Control in Transfusion Medicine, 2020.²²

All procedures and equipment in use must be validated prior to their implementation and periodically monitored thereafter. The contents of final blood components should be periodically assessed to make sure they meet the QC standards of blood components. 1% of the total components prepared should be checked for their quality. If the workload is < 500 donors per month then a minimum of four per month should be checked for components quality.

The RCCs should be discarded if the collection exceeds 15 minutes. Components should be prepared and stored within eight hours of the blood collection time.^{237,238} This usually happens in blood camps, so ensure that the components are prepared within time. The HCT of RCCs must be 55-79% to ensure sufficient nourishment and anticoagulant is available to keep the red cells viable for 35 days. QC should be checked of those components which have completed their shelf life. For RCCs collected in CPDA-1, the QC should be checked on the

35 or 36 days of their shelf life. If in-date units are selected, they must be given a final disposition and documented as 'used for quality control'. For RCCs, a segment is required after a thorough mixing from each blood unit with the appropriate segment number (segments must be made after the preparation of the RCCs, before making the segment strip the tubing by mixing blood and remaining plasma very well).

Procedure for QC Testing²²

- Every 100th bag (1% of the collected blood donations) should be checked or a minimum of four bags per month should be checked for quality control.
- For RCCs haematocrit testing, detach one segment (newly made from RCC not the original segment made from whole blood) from three or four donor units of different types, made on different shifts if possible.
- Take the contents of each segment and place into a 12" x 75" test tube which is properly labeled with each unit number and mix well.
- Run these samples on the haematology analyzer and record the results on the QC form (Table 3).

Table 3: RCC Quality Control Record Form

Parameter	Specification	Result
Volume	230-250 ml	
HCT	55-79%	
Haemolysis	< 0.8%	
Sterility	Sterile	
Clot	Absent	

- Specific gravity of packed red cells is 1.080.
- Acceptable results for RCCs QC: at least 100% of units tested should have HCT percentage less than 80% when collected in CPDA-1.
- For leucodepleted RCCs, all specifications are the same except residual WBC count which should be < 5x10⁶/L.
- Store at 2-6°C for up to 35 days (with CPDA-1).
- Visually inspect RCCs for physical haemolysis, clots, grossly lipemic (milky white colour) or signs of bacterial contamination of units by observing colour (brownish/purplish/murky or greyish) and consistency. Further, bag segments should also be

looked for signs of haemolysis (pinkish or reddish colour plasma).

- Record results on RCC Quality Control form as shown in Table 3 and included in the National Guidelines for Quality Control in Transfusion Medicine, 2020.

Hospital Transfusion Committee

Every hospital and health care facility responsible for the transfusion of blood components should have a transfusion committee in place. Hospital Transfusion Committees (HTCs) play a pivotal role in promoting safety and efficiency in blood transfusion therapy.¹⁹ The HTC is a key clinical governance element for oversight and delivery of safe transfusion within the hospital.²¹ They formulate appropriate local policies and procedures in accordance with the National Blood Policy and Clinical Use of Blood (CUB) Guidelines, regularly review and revise them and monitor hospital transfusion practices against them. HTC establishes and diffuses guidelines for requisition, handling, issuing, storage, and transfusion of blood and components as well as their traceability. HTC are a watchdog for promoting safe and appropriate transfusion of blood and components.

HTCs are an organizational concept and structure which can be set up with the proper resources of the hospital. They provide leadership and advocacy for good transfusion practices. Corresponding to the complexity of blood transfusion, HTCs are a multi-disciplinary team, involving all departments prescribing and providing blood products. They develop indicators of good practice at local level.

Hospital Transfusion Committees are a part of the Quality System for the management of the transfusion of blood and blood components. They are the moral authority at hospital for the implementation of good transfusion practices, haemovigilance and all required corrective actions within the hospital.²²

The HTC concept was born in the USA at the end of the 1970s, when quality management strategies began to be introduced for the management of health care units and hospitals. From the start, HTC was a quality tool to implement, at the hospital level, quality standards and practices in routine blood transfusion practices. HTC must promote the establishment of:

- Rules of governing good transfusion practices at the hospital level,
- Policies, guidelines, and procedures covering all the aspects of the day-to-day practices in transfusion medicine.
- Initial and continuous training of all staff regarding safe blood transfusion practices.
- Audits to follow up on the implementation of safe blood transfusion practices.

HTC has also been the structure through which the haemovigilance concept has been put to practice, and promoted, among all the health care units where blood transfusions are prescribed and used.²³ Thus, HTC is the best way to implement, at the hospital level, quality and safety in the blood transfusion. This also forms the basis of the WHO recommendation that a Transfusion Committee should be established in every hospital to, (i) implement the national blood policy, standards and guidelines; and (ii) monitor the use of blood and blood components at the local level.

Patient Blood Management

Patient Blood Management (PBM) is a relatively new concept in transfusion medicine. Prof. James Isbister, a haematologist from Australia first used the terminology 'Patient Blood Management' in 2005.²³⁹ PBM is a personalized, patient-focused approach now implemented globally across various clinical practices. PBM programmes are designed to encompass comprehensive patient care, covering preparation for procedures, surgeries, or obstetric management.

PBM aims to improve clinical outcomes for individual patients by managing and optimizing the patient's own blood as a standard of clinical care.²⁴⁰ While PBM is essentially rooted in basic clinical best practices, it often challenges long-standing habits and default transfusion approaches that have evolved over time.²⁴¹ PBM has been described, especially in the elective surgical setting, to include main components:²⁴²

- Enhancing the patient's red blood cell mass
- Reducing blood loss
- Managing and optimizing the patient's tolerance to anaemia

These strategies help minimize transfusion needs and improved patient outcomes. PBM is also increasingly applied to various medical conditions.²⁴³

PBM programmes aim to limit excessive blood sampling for laboratory tests and line flushing, promoting alternative solutions such as small-volume sample tubes and rationalizing blood test frequency.²⁴⁴ These measures help decrease the incidence and impact of iatrogenic anaemia and reduce the costs associated with frequent pathology testing.^{245,246} The World Health Organization (WHO) has published a policy brief titled 'The urgent need to implement patient blood management,' which provides comprehensive insights into PBM. This document emphasizes the importance of integrating PBM into healthcare systems to enhance patient outcomes and safety. For detailed information and guidance, the document can be accessed from the WHO website.²⁴⁷

Conclusion

In conclusion, these guidelines, developed by the BBMT-Pakistan's Working Group, provide a comprehensive framework to promote safe, efficient, and appropriate transfusion practices for the clinical use of RCCs. By adhering to these guidelines, healthcare providers can enhance patient outcomes, reduce risks associated with transfusions, and optimize the use of blood resources. The structured approach outlined ensures that transfusions are administered only when clinically necessary, upholding the highest standards of patient care and safety.

They emphasize the importance of informed consent, pre-transfusion protocols, and adherence to quality standards in handling and administering RCCs. These guidelines also underscore the necessity for collaboration between clinical teams, blood banks, and hospital transfusion services to maintain an adequate, safe blood supply while minimizing risks. The emphasis on patient-centred care involves detailed protocols for monitoring, documentation, and the management of adverse transfusion reactions, ensuring transfusions are only conducted when truly indicated. The incorporation of haemovigilance practices provides a mechanism for continuous quality improvement and error prevention across the transfusion chain. Recognizing the dynamic nature of medical practices and advancements, these guidelines are designed to be a living document, subject to regular reviews and updates. This ongoing revision will ensure alignment with current research, technology, and best practices, thereby maintaining the highest safety standards for both patients and healthcare providers.

References

- Grazzini G, Mannucci PM, Oleari F. Plasma-derived medicinal products: demand and clinical use. *Blood Transfus.* 2013 Suppl 4(Suppl 4):s2-5. <https://doi:10.2450/2013.002s>.
- El Ekiaby M, Diop S, Gouider E, Moftah F. Challenges associated with access to plasma-derived medicinal products in low middle-income and low-income countries. *Vox Sang.* 2024;119(2):166-170. <https://doi:10.1111/vox.13555>.
- Saba N, Nasir JA, Waheed U, Aslam S, Mohammad I, Wazeer A, Ahmed S, Nisar M. Seroprevalence of Transfusion-Transmitted Infections among Voluntary and Replacement Blood Donors at the Peshawar Regional Blood Centre, Khyber Pakhtunkhwa, Pakistan. *J Lab Physicians.* 2021;13(2):162-168. <https://doi:10.1055/s-0041-1729485>.
- Avery P, Morton S, Tucker H, Green L, Weaver A, Davenport R. Whole blood transfusion versus component therapy in adult trauma patients with acute major haemorrhage. *Emerg Med J.* 2020;37(6):370-378. <https://doi:10.1136/emered-2019-209040>.
- Tinegate H, Birchall J, Gray A, et al. Guideline on the investigation and management of acute transfusion reactions Prepared by the BCSH Blood Transfusion Task Force. *Br J Haematol.* 2012;159(2):143-153. <https://doi:10.1111/bjh.12017>.
- Kurup PA, Arun P, Gayathri NS, Dhanya CR, Indu AR. Modified formulation of CPDA for storage of whole blood, and of SAGM for storage of red blood cells, to maintain the concentration of 2,3-diphosphoglycerate. *Vox Sang.* 2003 ;85(4):253-61. <https://doi:10.1111/j.0042-9007.2003.00366.x>.
- D'Amici GM, Mirasole C, D'Alessandro A, Yoshida T, Dumont LJ, Zolla L. Red blood cell storage in SAGM and AS3: a comparison through the membrane two-dimensional electrophoresis proteome. *Blood Transfus.* 2012;10 Suppl 2(Suppl 2):s46-54. <https://doi:10.2450/2012.008S>.
- Himbert S, Qadri SM, Sheffield WP, Schubert P, D'Alessandro A, Rheinstädter MC. Blood bank storage of red blood cells increases RBC cytoplasmic membrane order and bending rigidity. *PLoS One.* 2021;16(11):e0259267. <https://doi:10.1371/journal.pone.0259267>.
- D'Alessandro A, Zimring JC, Busch M. Chronological storage age and metabolic age of stored red blood cells: are they the same? *Transfusion.* 2019;59(5):1620-1623.
- Kozlova E, Chernysh A, Moroz V, Kozlov A, Sergunova V, Sherstyukova E, Gudkova O. Two-step process of cytoskeletal structural damage during long-term storage of packed red blood cells. *Blood Transfus.* 2021;19(2):124-134. <https://doi:10.2450/2020.0220-20>.
- Hess JR. Red cell storage. *J Proteomics.* 2010;73(3):368-73. <https://doi:10.1016/j.jprot.2009.11.005>.
- Sharma RR, Marwaha N. Leukoreduced blood components: advantages and strategies for its implementation in developing countries. *Asian J Transfusion Sci.* 2010;4(1):3-8. <https://doi:10.4103/0973-6247.59384>.
- Hogshire L, Carson JL. Red blood cell transfusion: what is the evidence when to transfuse? *Curr Opin Hematol.* 2013;20:546-51. <https://doi:10.1097/MOH.0b013e32836508bd>.
- Wood EM, Ang AL, Bisht A, Bolton-Maggs PH, Bokhorst AG, Flesland O, Land K, Wiersum-Osselton JC, Schipperus MR, Tiberghien P, Whitaker BI. International haemovigilance: what have we learned and what do we need to do next? *Transfus Med.* 2019;29(4):221-230. <https://doi:10.1111/tme.12582>.
- Wood EM, Whitaker BI, Townsend M, Narayan S. How we forecast tomorrow's haemovigilance. *Transfus Clin Biol.* 2024 ;31(2):114-118. <https://doi:10.1016/j.traccli.2024.03.001>.
- Wood EM, Whitaker BI, Townsend M. Haemovigilance: Giving it our best SHOT! *Vox Sang.* 2023;118(4):260-262. <https://doi:10.1111/vox.13411>.
- Lassale B, Daurat G, Besse-Moreau M, Aullen JP. L'hémovigilance française de 1994 à nos jours : évolution et perspectives [French haemovigilance from 1994 to nowadays: Evolution and prospects]. *Transfus Clin Biol.* 2017 ;24(3):268-272. <https://doi:10.1016/j.traccli.2017.05.007>.
- Decadt I, Costermans E, Van de Poel M, Kesteloot K, Devos T. A haemovigilance team provides both significant financial and quality benefits in a University Hospital. *Transfus Apher Sci.* 2017;56(2):199-205. <https://doi:10.1016/j.transci.2016.11.006>.
- Rana R, Veluri Kishore SR, Kaur G, Singh G, Kumar R. Ensuring Safe Transfusion Practices through Haemovigilance: India vis-a-vis Global Scenario. *Curr Drug Saf.* 2023;18(4):474-483. <https://doi:10.2174/1574886318666221206114638>.
- Murphy MF. Hemovigilance drives improved transfusion safety. *Transfusion.* 2021;61(4):1333-1335. <https://doi:10.1111/trf.16322>.
- Vuk T, Politis C, Laspina S, Lozano M, Haddad A, de Angelis V, Garraud O; European and Mediterranean Initiative in Transfusion medicine (EMITm) group. Thirty years of hemovigilance - Achievements and future perspectives. *Transfus Clin Biol.* 2023;30(1):166-172. <https://doi:10.1016/j.traccli.2022.09.070>.
- Zaheer HA, Ahmed S, Waheed U, Wazeer A, Saba N. National Guidelines for Quality Control in Transfusion Medicine. 3rd Edition; 2020: Safe Blood Transfusion Programme, Ministry of National Health Services, Pakistan.
- Waheed U, Ahmed S, Saba N, Wazeer A, Qasim Z, Zaheer HA. Haemovigilance as a quality indicator in transfusion medicine: Pakistan's perspective. *Ann Pak Inst Med Sci.* 2020; 16(1): 46-51.
- Bossi D, Giardina B. Red cell physiology. *Mol Aspects Med.* 1996;17(2):117-28. [https://doi:10.1016/0098-2997\(96\)883439](https://doi:10.1016/0098-2997(96)883439).
- Flegel WA, Natanson C, Klein HG. Does prolonged storage of red blood cells cause harm? *Br J Haematol.* 2014 Apr;165(1):3-16. <https://doi:10.1111/bjh.12747>.
- Martí-Carvajal AJ, Simancas-Racines D, Peña-González BS. Prolonged storage of packed red blood cells for blood transfusion. *Cochrane Database Syst Rev.* 2015 ;2015(7):CD009330. <https://doi:10.1002/14651858.CD009330.pub2>.
- Yoshida T, Prudent M, D'Alessandro A. Red blood cell storage lesion: causes and potential clinical consequences. *Blood Transfus.* 2019 ;17(1):27-52. <https://doi:10.2450/2019.0217-18>.
- Merlo A, Losserand S, Yaya F, Connes P, Faivre M, Lorthois S, Minetti C, Nader E, Podgorski T, Renoux C, Coupier G, Franceschini E. Influence of storage and buffer composition on the mechanical behavior of flowing red blood cells. *Biophys J.* 2023;122(2):360-373. <https://doi:10.1016/j.bj.2022.12.005>.

29. Lagerberg JW, Korsten H, Van Der Meer PF, De Korte D. Prevention of red cell storage lesion: a comparison of five different additive solutions. *Blood Transfus.* 2017;15(5):456-462. <https://doi:10.2450/2017.0371-16>.
30. Pulliam KE, Joseph B, Makley AT, Caldwell CC, Lentsch AB, Goodman MD, Pritts TA. Washing packed red blood cells decreases red blood cell storage lesion formation. *Surgery.* 2021;169(3):666-670. <https://doi:10.1016/j.surg.2020.07.022>.
31. Moras E, Abbott JD, Vallabhajosyula S. AABB recommends restrictive RBC transfusions for hospitalized adults and children. *Ann Intern Med.* 2024;177(2):JC14. <https://doi:10.7326/J23-0116>.
32. Marik PE. Transfusion of Blood and Blood Products. Evidence-Based Critical Care. 2014:585–619. https://doi:10.1007/978-3-319-11020-2_38.
33. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK et al; Clinical Transfusion Medicine Committee of the AABB. Red blood cell transfusion: a clinical practice guideline from the AABB*. *Ann Intern Med.* 2012;157(1):49-58. <https://doi:10.7326/0003-4819-157-1-201206190-00429>.
34. Carson JL, Stanworth SJ, Guyatt G, Valentine S, Dennis J, Bakhtary S, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. *JAMA.* 2023;330(19):1892-1902. <https://doi:10.1001/jama.2023.12914>.
35. Carson JL, Stanworth SJ, Dennis JA, Trivella M, Roubinian N, Fergusson DA, Triulzi D, Dorée C, Hébert PC. Transfusion thresholds for guiding red blood cell transfusion. *Cochrane Database Syst Rev.* 2021;12(12):CD002042. <https://doi:10.1002/14651858.CD002042.pub5>.
36. New HV, Berryman J, Bolton-Maggs PH, Cantwell C, Chalmers EA, Davies T, et al; British Committee for Standards in Haematology. Guidelines on transfusion for fetuses, neonates and older children. *Br J Haematol.* 2016;175(5):784-828. <https://doi:10.1111/bjh.14233>.
37. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the transfusion of red blood cells. *Blood Transfus.* 2009;7(1):49-64. <https://doi:10.2450/2008.0020-08>.
38. Vasan PK, Rajasekaran S, Viswanathan VK, Shetty AP, Kanna RM. Is fresh, leucodepleted, whole blood transfusion superior to blood component transfusion in pediatric patients undergoing spinal deformity surgeries? A prospective, randomized study analyzing postoperative serological parameters and clinical recovery. *Eur Spine J.* 2021;30(7):1943-1949. <https://doi:10.1007/s00586-021-06798-0>.
39. Patel NN, Murphy GJ. Evidence-Based Red Blood Cell Transfusion Practices in Cardiac Surgery. *Transfus Med Rev.* 2017;31(4):230-235. <https://doi:10.1016/j.tmr.2017.06.001>.
40. Nigam A, Prakash A, Saxena P. Blood transfusion in obstetrics. *Kathmandu Univ Med J (KUMJ).* 2013;11(44):355-9. <https://doi:10.3126/kumj.v11i4.13484>.
41. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev.* 2016;10(10):CD002042. <https://doi:10.1002/14651858.CD002042.pub4>.
42. Goodnough LT, Panigrahi AK. Blood Transfusion Therapy. *Med Clin North Am.* 2017;101(2):431-447. <https://doi:10.1016/j.mcna.2016.09.012>.
43. Mueller MM, Van Remoortel H, Meybohm P, Aranko K, Aubron C, Burger R, et al; ICC PBM Frankfurt 2018 Group. Patient Blood Management: Recommendations from the 2018 Frankfurt Consensus Conference. *JAMA.* 2019;321(10):983-997. <https://doi:10.1001/jama.2019.0554>.
44. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al: Red Blood Cell Transfusion Thresholds and Storage. *JAMA.* 2016;316(19):2025-2035. <https://doi:10.1001/jama.2016.9185>.
45. Raval JS, Griggs JR, Fleg A. Blood Product Transfusion in Adults: Indications, Adverse Reactions, and Modifications. *Am Fam Physician.* 2020;102(1):30-38.
46. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev.* 2012;4(4):CD002042. <https://doi:10.1002/14651858.CD002042.pub3>.
47. Arynov A, Kaidarova D, Kabon B. Alternative blood transfusion triggers: a narrative review. *BMC Anesthesiol.* 2024;24(1):71. <https://doi:10.1186/s12871-024-02447-3>.
48. Shah A, Stanworth SJ, McKechnie S. Evidence and triggers for the transfusion of blood and blood products. *Anaesthesia.* 2015;70 Suppl 1:10-9, e3-5. <https://doi:10.1111/anae.12893>.
49. Wang T, Luo L, Huang H, Yu J, Pan C, Cai X, et al. Perioperative blood transfusion is associated with worse clinical outcomes in resected lung cancer. *Ann Thorac Surg.* 2014;97(5):1827-37. <https://doi:10.1016/j.athoracsur.2013.12.044>.
50. Tanhehco YC. Red Blood Cell Transfusion. *Clin Lab Med.* 2021;41(4):611-619. <https://doi:10.1016/j.cll.2021.07.004>.
51. Practice guidelines for perioperative blood transfusion and adjuvant therapies: An updated report by the American Society of Anesthesiologists Task Force on perioperative blood transfusion and adjuvant therapies. *Anesthesiology.* 2006;105:198–208.
52. Sharma S, Sharma P, Tyler LN. Transfusion of blood and blood products: indications and complications. *Am Fam Physician.* 2011;83(6):719-24.
53. Autologous Blood Transfusion for Postpartum Hemorrhage. *MCN Am J Matern Child Nurs.* 2017;42(5):E20-E21. <https://doi:10.1097/NMC.0000000000000384>.
54. Rath WH. Postpartum hemorrhage—update on problems of definitions and diagnosis. *Acta Obstet Gynecol Scand.* 2011;90:421-428.
55. Schorn MN. Measurement of blood loss: Review of the literature. *J Midwifery Womens Health.* 2010;55:20–27.
56. Patterson JA, Roberts CL, Bowen JR, Irving DO, Isbister JP, et al. Blood transfusion during pregnancy, birth, and the postnatal period. *Obstet Gynecol.* 2014;123(1):126-133. <https://doi:10.1097/AOG.0000000000000054>.
57. Lu Q, Zhang J, Gao WM, Lv Y, Zhang XF, Liu XM. Intraoperative Blood Transfusion and Postoperative Morbidity Following Liver Resection. *Med Sci Monit.* 2018;24:8469-8480. <https://doi:10.12659/MSM.910978>.
58. Merolle L, Marraccini C, Di Bartolomeo E, Montella MT, Pertinhez TA, Baricchi R, et al. Postoperative patient blood management: transfusion appropriateness in cancer patients. *Blood Transfus.* 2018;18(5):359-365. <https://doi:10.2450/2020.0048-20>.
59. Gregersen M. Postoperative red blood cell transfusion strategy in frail anemic elderly with hip fracture. A randomized controlled trial. *Dan Med J.* 2016;63(4):B5221.
60. Hebert PC, Van der Linden P, Biro G, Hu LQ. Physiologic aspects of anemia. *Crit Care Clin.* 2004;20:187–212.
61. Duffin J. Fail-safe aspects of oxygen supply. *J Physiol.* 2020;598(21):4859-4867. <https://doi:10.1113/JP280301>.

62. Allardet-Servent J, Sicard G, Metz V, Chiche L. Benefits and risks of oxygen therapy during acute medical illness: Just a matter of dose! *Rev Med Interne*. 2019;40(10):670-676. <https://doi:10.1016/j.revmed.2019.04.003>.
63. Robinson D, Basso M, Chan C, Duckitt K, Lett R. Guideline No. 431: Postpartum hemorrhage and hemorrhagic shock. *J Obstet Gynaecol Can*. 2022;44(12):1293-1310.e1. <https://doi:10.1016/j.jogc.2022.10.002>. Erratum in: *J Obstet Gynaecol Can*. 2023;45(3):241. <https://doi:10.1016/j.jogc.2023.02.008>.
64. Surbek D, Vial Y, Girard T, Breyman C, Bencaiova GA, Baud D, et al. Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion. *Arch Gynecol Obstet*. 2020;301(2):627-641. <https://doi:10.1007/s00404-019-05374-8>.
65. Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Ferraris VA, Ferraris SP, Saha SP, Hessel EA 2nd, Haan CK, et al; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion; Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, Hill SE, Body S. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. *Ann Thorac Surg*. 2007;83(5 Suppl):S27-86. <https://doi:10.1016/j.athoracsur.2007.02.099>.
66. Wischmann P, Bruno RR, Wernly B, Wolff G, Afzal S, Rezar R, et al. Relevance of pre-existing anaemia for patients admitted for acute coronary syndrome to an intensive care unit: a retrospective cohort analysis of 7418 patients. *Eur Heart J Open*. 2022;2(4):oeac040. <https://doi:10.1093/ehjopen/oeac040>.
67. Hokland P, Daar S, Khair W, Sheth S, Taher AT, Torti L, et al. Thalassaemia-A global view. *Br J Haematol*. 2023;201(2):199-214. <https://doi:10.1111/bjh.18671>.
68. Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β -thalassaemia. *Blood Rev*. 2019;37:100588. <https://doi:10.1016/j.blre.2019.100588>.
69. Foong WC, Loh CK, Ho JJ, Lau DS. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias. *Cochrane Database Syst Rev*. 2023;1(1):CD013767. <https://doi:10.1002/14651858.CD013767.pub2>.
70. Motta I, Bou-Fakhredin R, Taher AT, Cappellini MD. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation. *Drugs*. 2020;80(11):1053-1063. <https://doi:10.1007/s40265-020-01341-9>.
71. Cornell N, Eisenhut M, Ramprakash S. Variation in Transfusion Requirements Among Children With Thalassemia on Regular Transfusion Programs: Which Formula Closely Predicts the Actual Requirements? *J Pediatr Hematol Oncol*. 2017;39(7):e388-e390. <https://doi:10.1097/MPH.0000000000000746>.
72. Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: A critical review of the literature and transfusion guideline. *Transfus Med Rev*. 2007;21:118-33.
73. Linder GE, Chou ST. Red cell transfusion and alloimmunization in sickle cell disease. *Haematologica*. 2021;106(7):1805-1815. <https://doi:10.3324/haematol.2020.270546>.
74. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. *Nat Rev Dis Primers*. 2018;4:18010. <https://doi:10.1038/nrdp.2018.10>.
75. Davis BA, Allard S, Qureshi A, Porter JB, Pancham Win, Cho G, et al. British Society for Haematology Guidelines on red cell transfusion in sickle cell disease Part II: indications for transfusion. *Br J Haematol*. 2017;176(2):192-209. <https://doi:10.1111/bjh.14383>.
76. Elendu C, Amaechi DC, Alakwe-Ojimba CE, Elendu TC, Elendu RC, Ayabazu CP, et al. Understanding Sickle cell disease: Causes, symptoms, and treatment options. *Medicine (Baltimore)*. 2023;102(38):e35237. <https://doi:10.1097/MD.00000000000035237>.
77. Thorvaldsson HH, Vidarsson B, Sveinsdottir SV, Olafsson GB, Halldorsdottir AM. Red blood cell utilization and transfusion triggers in patients diagnosed with chronic lymphocytic leukaemia in Iceland 2003-2016. *Vox Sang*. 2019;114(5):495-504. <https://doi:10.1111/vox.12775>.
78. Wallis JP. Red cell transfusion triggers. *Transfus Apher Sci*. 2008;39(2):151-4. <https://doi:10.1016/j.transci.2008.06.004>.
79. Oud JA, Evers D, Middelburg RA, de Vooght KMK, van de Kerkhof D, Visser O, et al. Association between renal failure and red blood cell alloimmunization among newly transfused patients. *Transfusion*. 2021;61(1):35-41. <https://doi:10.1111/trf.16166>.
80. Gill KS, Muntner P, Lafayette RA, Petersen J, Fink JC, Gilbertson DT, et al. Red blood cell transfusion use in patients with chronic kidney disease. *Nephrol Dial Transplant*. 2013;28(6):1504-15. <https://doi:10.1093/ndt/gfs580>.
81. Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al; British Society for Standards in Haematology. Guidelines for the diagnosis and management of adult aplastic anaemia. *Br J Haematol*. 2016;172(2):187-207. <https://doi:10.1111/bjh.13853>.
82. Moncharmont P, Quittançon E, Barday G, Benamara A; les Correspondants d'Hémovigilance et de sécurité et al. Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes. *Vox Sang*. 2019;114(4):349-354. <https://doi:10.1111/vox.12765>.
83. Anand S, Burkenroad A, Glaspy J. Workup of anemia in cancer. *Clin Adv Hematol Oncol*. 2020;18(10):640-646.
84. Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. *Blood*. 2020;136(7):801-813. <https://doi:10.1182/blood.2019004017>.
85. British Committee for Standards in Haematology; Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. Guidelines on the management of massive blood loss. *Br J Haematol*. 2006;135(5):634-41. <https://doi:10.1111/j.1365-2141.2006.06355.x>.
86. Hofer S, Blaha J, Collins PW, Ducloy-Bouthors AS, Guasch E, Labate F, et al. Haemostatic support in postpartum haemorrhage: A review of the literature and expert opinion. *Eur J Anaesthesiol*. 2023;40(1):29-38. <https://doi:10.1097/EJA.0000000000001744>.
87. Rehan M, Iqbal T, Sarwar M, Khan MS, Tariq MH, Ain Q, et al. Pattern of acute adverse transfusion reactions in patients with burn injuries: A novel initiative towards haemovigilance at the National Burn Centre of Pakistan. *Ann Burns Fire Disasters*. 2023;36(3):261-265.
88. Palmieri TL. Burn injury and blood transfusion. *Curr Opin Anaesthesiol*. 2019;32(2):247-251. <https://doi:10.1097/ACO.0000000000000701>.
89. Tichil I, Rus IC, Cenariu D, Fodor L, Mitre I. Blood transfusions in non-major burns patients. *Burns*. 2023;49(8):1808-1815. <https://doi:10.1016/j.burns.2023.09.018>.

90. Tavousi SH, Ahmadabadi A, Sedaghat A, Khadem-Rezaiyan M, Yaghoubi Moghaddam Z, Behrouzian MJ, et al. Blood transfusion in burn patients: Triggers of transfusion in a referral burn center in Iran. *Transfus Clin Biol*. 2018;25(1):58-62. <https://doi:10.1016/j.traccli.2017.07.003>.
91. Council of Europe. Recommendation No. R(95)15. The Guide to the preparation, use and quality assurance of blood components. 21st ed. 2023. Available from: https://freepub.edqm.eu/publications/AUTOPUB_48/detail. [cited 2024 Oct 4].
92. Waheed U, Wazeer A, Khan R, N Saba N, Qasim Z. Effectiveness of leucodepletion filters in reducing adverse transfusion reactions in multi-transfused beta thalassaemia major patients. *Vox Sanguinis* 2024; 119 (Suppl. S1): p 538. <https://doi.org/10.1111/vox.13650>.
93. Williamson LM, Wimperis JZ, Williamson P. Bedside filtration of blood products in the prevention of HLA alloimmunization—a prospective randomized study. *Alloimmunisation Study Group*. 1994;83:3028–3035.
94. Bohoněk M, Petráš M, Turek I, Urbanová J, Hrádek T, Staropražská V, et al. In vitro parameters of cryopreserved leucodepleted and non-leucodepleted red blood cells collected by apheresis or from whole blood and stored in AS-3 for 21 days after thawing. *Blood Transfus*. 2014;12 Suppl 1(Suppl 1):s199-203. <https://doi:10.2450/2013.0106-12>.
95. Mutlu B, Günlemez A, Türker G, Gökalp AS, Willke A. Riskli gruplara sitomegalovirus seronegatif kan transfüzyonu için bağışçı kanlarında tarama gerekli mi? [Is serologic screening necessary in the donor bloods for cytomegalovirus seronegative blood transfusion to risky patients?]. *Mikrobiyol Bul*. 2008;42(2):337-41.
96. Shah A, Brunskill SJ, Desborough MJ, Doree C, Trivella M, Stanworth SJ. Transfusion of red blood cells stored for shorter versus longer duration for all conditions. *Cochrane Database Syst Rev*. 2018;12(12):CD010801. <https://doi:10.1002/14651858.CD010801.pub3>.
97. Roback JD. CMV and blood transfusions. *Rev Med Virol*. 2002 ;12(4):211-9. <https://doi:10.1002/rmv.353>.
98. Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, Dini G. Cytomegalovirus infection after bone marrow transplantation in children. *Hum Immunol*. 2004;65(5):416-22. <https://doi:10.1016/j.humimm.2004.02.013>.
99. Zantomio D, Bayly E, Wong K, Spencer A, Ritchie D, Morgan S, et al. Centre-based comparison of double versus single prevention strategy on transfusion-transmitted cytomegalovirus in at-risk haemopoietic stem cell transplant patients and a state survey on cytomegalovirus-seronegative ordering practises. *Intern Med J*. 2023;53(5):717-722. <https://doi:10.1111/imi.15751>.
100. Hillyer CD, Snyderman DR, Berkman EM. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: transfusion of blood products. *Transfusion*. 1990;30(7):659-66. <https://doi:10.1046/j.1537-2995.1990.30790385528.x>.
101. Adkins BD, Jacobs JW, Booth GS, Savani BN, Stephens LD. Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review. *Clin Hematol Int*. 2024;6(1):128-140. <https://doi:10.46989/001c.94135>.
102. Teodoro N, Sudhof L, Shainker SA. Intrauterine Fetal Transfusion. *Neoreviews*. 2019;20(10):e612-e614. <https://doi:10.1542/neo.20-10-e612>.
103. Prefumo F, Fichera A, Fratelli N, Sartori E. Fetal anemia: Diagnosis and management. *Best Pract Res Clin Obstet Gynaecol*. 2019;58:2-14. <https://doi:10.1016/j.bpobgyn.2019.01.001>.
104. Sobhani NC, Zakieh A, Bakhtary S, Gonzalez JM. Intrauterine transfusion practice patterns in the United States. *Am J Obstet Gynecol MFM*. 2022;4(4):100655. <https://doi:10.1016/j.ajogmf.2022.100655>.
105. Lindenburg IT, van Kamp IL, Oepkes D. Intrauterine blood transfusion: current indications and associated risks. *Fetal Diagn Ther*. 2014;36(4):263-71. <https://doi:10.1159/000362812>.
106. Foukanelli T, Kerr P, Bolton-Maggs PHB, Cardigan R, Coles A, Gennery A, et al. Guidelines on the use of irradiated blood components. *Br J Haematol*. 2020;191(5):704-724. <https://doi:10.1111/bjh.17015>.
107. Manduzio P. Transfusion-associated graft-versus-host disease: A concise review. *Hematol Rep*. 2018;10(4):7724. <https://doi:10.4081/hr.2018.7724>.
108. Mittal A, Verma S, Natanasabapathi G, Kumar P, Verma AK. Diacetylene-Based Colorimetric Radiation Sensors for the Detection and Measurement of γ Radiation during Blood Irradiation. *ACS Omega*. 2021;6(14):9482-9491. <https://doi:10.1021/acsomega.0c06184>.
109. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. *BCSH Blood Transfusion Task Force*. *Transfus Med*. 1996;6(3):261-71.
110. Jang S, Woo S, Lee YH, Yang S, Jin YW. Transfusion of γ -irradiated blood components to individuals does not compromise the cytogenetic dose assessment. *Mutat Res Genet Toxicol Environ Mutagen*. 2021;863-864:503312. <https://doi:10.1016/j.mrgentox.2021.503312>.
111. Kirpalani HM, Prokopchuk-Gauk O, Heddle NM. Use of Irradiated Red Blood Cell Transfusions in Newborns to Improve Intracerebral Saturation. *JAMA Pediatr*. 2022 ;176(5):e220149. <https://doi:10.1001/jamapediatrics.2022.0149>.
112. Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone? *Transfus Apher Sci*. 2022 ;61(2):103402. <https://doi:10.1016/j.transci.2022.103402>.
113. Sunul H, Erguven N. Transfusion-associated graft-versus-host disease. *Transfus Apher Sci*. 2013;49(2):331-3. <https://doi:10.1016/j.transci.2013.07.001>.
114. Baker SA, Wong LK, Wieland R, Bulterys P, Allard L, Nguyen L, et al. Validated transport conditions maintain the quality of washed red blood cells. *Transfusion*. 2022;62(9):1860-1870. <https://doi:10.1111/trf.17062>.
115. Stark MJ, Collins CT, Andersen CC, Crawford TM, Sullivan TR, Bednarz J, et al. Study protocol of the WashT Trial: transfusion with washed versus unwashed red blood cells to reduce morbidity and mortality in infants born less than 28 weeks' gestation - a multicentre, blinded, parallel group, randomised controlled trial. *BMJ Open*. 2023;13(7):e070272. <https://doi:10.1136/bmjopen-2022-070272>.
116. Karsten E, Breen E, Herbert BR. Red blood cells are dynamic reservoirs of cytokines. *Sci Rep*. 2018;8(1):3101. <https://doi:10.1038/s41598-018-21387-w>.
117. Larsson L, Ohlsson S, Andersson TN, Watz E, Larsson S, Sandgren P, et al. Pathogen reduced red blood cells as an alternative to irradiated and washed components with

- potential for up to 42 days storage. *Blood Transfus.* 2024;22(2):130-139. <https://doi:10.2450/BloodTransfus.479>.
118. Hansen AL, Turner TR, Kurach JD, Acker JP. Quality of red blood cells washed using a second wash sequence on an automated cell processor. *Transfusion.* 2015;55(10):2415-21. <https://doi:10.1111/trf.13166>.
 119. Nair SS, Sreedevi V, Nagesh DS. Warming of blood and intravenous fluids using low-power infra-red light-emitting diodes. *J Med Eng Technol.* 2021;45(8):614-626. <https://doi:10.1080/03091902.2021.1936675>.
 120. Burbridge MA, Panigrahi AK, Stone SA, Jaffe RA, Brock-Utne J. Rapid Blood Transfusion: The Importance of Hemodilution and Needleless Connectors. *Cureus.* 2021;13(3):e13999. <https://doi:10.7759/cureus.13999>.
 121. Roxby D, Sobieraj-Teague M, von Wielligh J, Sinha R, Kuss B, Smith AL, et al. Warming blood prior to transfusion using latent heat. *Emerg Med Australas.* 2020;32(4):604-610. <https://doi:10.1111/1742-6723.13471>.
 122. Holcomb JB, Tilley BC, Baraniuk S. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA.* 2015;313(5):471-482. <https://doi:10.1001/jama.2015.12>.
 123. Hulse W, Bahr TM, Fredrickson L, Canfield CM, Friddle K, Pysher TJ, et al. Warming blood products for transfusion to neonates: In vitro assessments. *Transfusion.* 2020 ;60(9):1924-1928. <https://doi:10.1111/trf.16007>.
 124. Gulliksson H, Nordahl-Källman AS. Effect of transient warming of red blood cells for up to 24 h: in vitro characteristics in CPD/saline-adenine-glucose-mannitol environment. *Vox Sang.* 2014;106(1):61-7. <https://doi:10.1111/vox.12079>.
 125. Ingram A, Harper M. The health economic benefits of perioperative patient warming for prevention of blood loss and transfusion requirements as a consequence of inadvertent perioperative hypothermia. *J Perioper Pract.* 2018;28(9):215-222. <https://doi:10.1177/1750458918776558>.
 126. Pires MPO, Peterlini MAS, Ullman AJ, Bulmer AC, Rickard CM, Pedreira MLG. Effect of warming and infusion of red blood cell concentrates on markers of haemolysis: An ex vivo simulation study. *Aust Crit Care.* 2021;34(3):235-240. <https://doi:10.1016/j.aucc.2020.08.003>.
 127. Elzik ME, Dirschl DR, Dahners LE. Correlation of transfusion volume to change in hematocrit. *Am J Hematol.* 2006;81(2):145-6. <https://doi:10.1002/ajh.20517>.
 128. Gosmann F, Nørgaard A, Rasmussen MB, Rahbek C, Seeberg J, Møller T. Transfusion-associated circulatory overload in adult, medical emergency patients with perspectives on early warning practice: a single-centre, clinical study. *Blood Transfus.* 2018;16(2):137-144. <https://doi:10.2450/2017.0228-16>.
 129. Simpson JD, Hopkins A, Amil A, Ross B, Enjeti AK. Transfusion-associated circulatory overload in ambulatory patients. *Vox Sang.* 2019;114(3):216-222. <https://doi:10.1111/vox.12753>.
 130. Piccin A, Cronin M, Brady R, Sweeney J, Marcheselli L, Lawlor E. Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance Office 2000 to 2010. *Transfusion.* 2015;55(6):1223-30. <https://doi:10.1111/trf.12965>.
 131. Mokhtar G, Adly A, Baky AA, Ezzat D, Hakeem GA, Hassab H, et al; Egyptian Pediatric Clinical Practice Guidelines Committee (EPG). Transfusion of blood components in pediatric age groups: an evidence-based clinical practice guideline adapted for the use in Egypt using 'Adapted ADAPTE'. *Ann Hematol.* 2024;103(4):1373-1388. <https://doi:10.1007/s00277-024-05657-4>.
 132. Valentine SL, Bembea MM, Muszynski JA. Consensus recommendations for RBC transfusion practice in critically ill children from the pediatric critical care transfusion and anemia expertise initiative. *Pediatr Critic Care Med.* 2018;19(9):884-898. <https://doi:10.1097/PCC.0000000000001613>.
 133. New HV, Berryman J, Bolton-Maggs PH. Guidelines on transfusion for fetuses, neonates and older children. *Br J Haematol.* 2016;175(5):784-828. <https://doi:10.1111/bjh.14233>.
 134. Rajan M, Singh J, Singh Dalal J. Exchange blood transfusion in neonates with severe hyperbilirubinemia in a lower-middle-income country: can we minimise the incidence? *Trop Doct.* 2021;51(2):146-150. <https://doi:10.1177/0049475520959731>.
 135. Kim MS, Chung Y, Kim H, Ko DH, Jung E, Lee BS, et al. Neonatal exchange transfusion: Experience in Korea. *Transfus Apher Sci.* 2020;59(3):102730. <https://doi:10.1016/j.transci.2020.102730>.
 136. Rowan MS, Carter A. Evaluation of the red blood cell and plasma transfusion guidelines. *Int J Qual Health Care.* 2000;12(1):11-7. <https://doi:10.1093/intqhc/12.1.11>.
 137. Mo YD, Delaney M. Transfusion in Pediatric Patients: Review of Evidence-Based Guidelines. *Clin Lab Med.* 2021;41(1):1-14. <https://doi:10.1016/j.cll.2020.10.001>.
 138. Koo BN, Kwon MA, Kim SH, Kim JY, Moon YJ, Park SY, et al. Korean clinical practice guideline for perioperative red blood cell transfusion from Korean Society of Anesthesiologists. *Korean J Anesthesiol.* 2019;72(2):91-118. <https://doi:10.4097/kja.d.18.00322>.
 139. Davies P, Robertson S, Hegde S, Greenwood R, Massey E, Davis P. Calculating the required transfusion volume in children. *Transfusion.* 2007;47(2):212-6. <https://doi:10.1111/j.1537-2995.2007.01091.x>.
 140. Kruimer DM, Stavleu DC, Mulder RL, Kremer LCM, Tissing WJE, Loeffen EAH; prophylactic red blood cell transfusion guideline panel. Prophylactic red blood cell transfusions in children and neonates with cancer: An evidence-based clinical practice guideline. *Support Care Cancer.* 2024;32(11):766. <https://doi:10.1007/s00520-024-08888-3>.
 141. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the transfusion of red blood cells. *Blood Transfus.* 2009;7(1):49-64. <https://doi:10.2450/2008.0020-08>.
 142. Kanbur NA, Gelen SA, Zengin E, Sarper N. Pedipacks in the transfusion of pediatric patients to reduce wastage of blood components: an observational study from a tertiary center. *Turk J Pediatr.* 2022;64(5):869-875. <https://doi:10.24953/turkiped.2022.195>.
 143. Gulucu S, Uzun KE. Evaluation of blood transfusion rate in obstetric patients. *Ginekol Pol.* 2022;93(8):637-642. <https://doi:10.5603/GP.a2021.0261>.
 144. Kłoka JA, Friedrichson B, Jasny T, Old O, Piekarski F, Zacharowski K, et al. Anemia, red blood cell transfusion and administration of blood products in obstetrics: a nationwide analysis of more than 6 million cases from 2011-2020. *Blood Transfus.* 2024;22(1):37-45. <https://doi:10.2450/BloodTransfus.528>.

145. Birch C, Hogan C, Mahoney G. Co-administration of drugs and blood products. *Anaesth Intensive Care*. 2001;29(2):137-40. <https://doi:10.1177/0310057X0102900207>.
146. Brunskill SJ, Wilkinson KL, Doree C, Trivella M, Stanworth S. Transfusion of fresher versus older red blood cells for all conditions. *Cochrane Database Syst Rev*. 2015;(5):CD010801. <https://doi:10.1002/14651858.CD010801.pub2>. Update in: *Cochrane Database Syst Rev*. 2018;12:CD010801. <https://doi:10.1002/14651858.CD010801.pub>.
147. Flegel WA. Fresh blood for transfusion: how old is too old for red blood cell units? *Blood Transfus*. 2012;10(3):247-251. <https://doi:10.2450/2012.0105-12>.
148. Alexander PE, Barty R, Fei Y, Vandvik PO, Pai M, Siemieniuk RA, et al. Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. *Blood*. 2016;127(4):400-10. <https://doi:10.1182/blood-2015-09-670950>.
149. McQuilten ZK, French CJ, Nichol A, Higgins A, Cooper DJ. Effect of age of red cells for transfusion on patient outcomes: a systematic review and meta-analysis. *Transfus Med Rev*. 2018 Apr;32(2):77-88. <https://doi:10.1016/j.tmr.2018.02.002>. Epub 2018 Feb 17. Erratum in: *Transfus Med Rev*. 2020 ;34(2):138-139. <https://doi:10.1016/j.tmr.2020.03.002>.
150. Mishra S, Daga A, Gupta A. Inventory management practices in the blood bank of an institute of national importance in India. *J Family Med Prim Care*. 2021;10(12):4489-4492. https://doi:10.4103/jfmpc.jfmpc_1000_21.
151. Sarhangian V, Abouee-Mehrizi H, Baron O, Berman O, Heddle NM, Barty R. Reducing the age of transfused red blood cells in hospitals: ordering and allocation policies. *Vox Sang*. 2016 ;110(4):385-92. <https://doi:10.1111/vox.12374>.
152. Rolfsson Ó, Johannsson F, Magnúsdóttir M, Paglia G, Sigurjonsson ÓE, Bordbar A, et al. Mannose and fructose metabolism in red blood cells during cold storage in SAGM. *Transfusion*. 2017;57(11):2665-2676. <https://doi:10.1111/trf.14266>.
153. D'Alessandro A, D'Amici GM, Vaglio S, Zolla L. Time-course investigation of SAGM-stored leukocyte-filtered red blood cell concentrates: from metabolism to proteomics. *Haematologica*. 2012;97(1):107-15. <https://doi:10.3324/haematol.2011.051789>.
154. Hansen AL, Turner TR, Yi QL, Acker JP. Quality of red blood cells washed using an automated cell processor with and without irradiation. *Transfusion*. 2014;54(6):1585-94. <https://doi:10.1111/trf.12489>.
155. Wolf J, Geneen LJ, Meli A, Doree C, Cardigan R, New HV. Hyperkalaemia Following Blood Transfusion-a Systematic Review Assessing Evidence and Risks. *Transfus Med Rev*. 2022 ;36(3):133-142. <https://doi:10.1016/j.tmr.2022.04.003>.
156. Swindell CG, Barker TA, McGuirk SP, Jones TJ, Barron DJ, Brawn WJ, et al. Washing of irradiated red blood cells prevents hyperkalaemia during cardiopulmonary bypass in neonates and infants undergoing surgery for complex congenital heart disease. *Eur J Cardiothorac Surg*. 2007 ;31(4):659-64. <https://doi:10.1016/j.ejcts.2007.01.014>.
157. Lagerberg JW. Frozen Blood Reserves. *Methods Mol Biol*. 2021;2180:523-538. https://doi:10.1007/978-1-071607831_26.
158. Gurevich V, Bertolini J, Lyons K. Determination of Fc function with frozen red blood cells. *Biologicals*. 2006;34(3):221-2. <https://doi:10.1016/j.biologicals.2005.11.003>.
159. Blood transfusion precautions to take. *Johns Hopkins Med Lett Health After 50*. 2014;26(7):6.
160. Posey DH Jr. Blood transfusion: uses, abuses, and hazards. *J Natl Med Assoc*. 1989;81(7):793-6.
161. Orlov YP, Lukach VN, Govorova NV, Baytugaeva GA. [Fear of anemia or why don't we afraid of blood transfusion?]. *Khirurgiia (Mosk)*. 2015;(11):88-94. Russian. <https://doi:10.17116/hirurgia20151188-94>.
162. Carman M, Uhlenbrock JS, McClintock SM. CE: A Review of Current Practice in Transfusion Therapy. *Am J Nurs*. 2018 ;118(5):36-44. <https://doi:10.1097/01.NAJ.0000532808.81713.fc>.
163. Sawant RB, Jathar SK, Rajadhyaksha SB, Kadam PT. Red cell hemolysis during processing and storage. *Asian J Transfus Sci*. 2007;1(2):47-51. <https://doi:10.4103/0973-6247.33446>.
164. Acker JP, Marks DC, Sheffield WP. Quality Assessment of Established and Emerging Blood Components for Transfusion. *J Blood Transfus*. 2016;2016:4860284. <https://doi:10.1155/2016/4860284>.
165. Wenz B. Clinical and laboratory precautions that reduce the adverse reactions, alloimmunization, infectivity, and possibly immunomodulation associated with homologous transfusions. *Transfus Med Rev*. 1990;4(4 Suppl 1):3-7. [https://doi:10.1016/s0887-7963\(90\)70236-2](https://doi:10.1016/s0887-7963(90)70236-2).
166. Johnston DG. Blood transfusion: use and abuse of blood components. *West J Med*. 1978;128(5):390-8.
167. Karim F, Adil SN. Eliminating wrong blood transfusions - recent advances. *J Pak Med Assoc*. 2017 May;67(5):659-660.
168. Stanworth SJ, Walwyn R, Grant-Casey J, Hartley S, Moreau L, Lorencatto F, et al; AFFINITIE Collaborators. Effectiveness of Enhanced Performance Feedback on Appropriate Use of Blood Transfusions: A Comparison of 2 Cluster Randomized Trials. *JAMA Netw Open*. 2022;5(2):e220364. <https://doi:10.1001/jamanetworkopen.2022.0364>.
169. International Society of Blood Transfusion. Adverse effects of transfusion [Internet]. Available from: <https://www.isbtweb.org/resources/educational-modules-on-clinical-use-of-blood/adverse-effects-of-transfusion.html> #References [cited 2024 Oct 13].
170. DeLisle J. Is This a Blood Transfusion Reaction? Don't Hesitate; Check It Out. *J Infus Nurs*. 2018;41(1):43-51. <https://doi:10.1097/NAN.0000000000000261>.
171. Bockhold C, Crumpler S. Responding to pulmonary-related blood transfusion reactions. *Nursing*. 2015;45(9):36-41; quiz 41-2. <https://doi:10.1097/01.NURSE.0000470412.33450.b1>.
172. Delaney M, Wendel S, Bercovitz RS, Cid J, Cohn C, Dunbar NM, et al; Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Transfusion reactions: prevention, diagnosis, and treatment. *Lancet*. 388(10061):2825-2836. [https://doi:10.1016/S0140-6736\(15\)01313-6](https://doi:10.1016/S0140-6736(15)01313-6).
173. Suddock JT, Crookston KP. Transfusion Reactions. 2023. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
174. Ackfeld T, Schmutz T, Guechi Y, Le Terrier C. Blood Transfusion Reactions-A Comprehensive Review of the Literature including a Swiss Perspective. *J Clin Med*. 2022 ;11(10):2859. <https://doi:10.3390/jcm11102859>.
175. Hsieh MY, Chen JS, Yin CH. Investigation of the patients with recurrent acute transfusion reactions: A single tertiary medical centre experience. *J Int Med Res*. 2023 ;51(7):3000605231181733. <https://doi:10.1177/03000605231181733>.

176. Menendez JB, Edwards B. Early Identification of Acute Hemolytic Transfusion Reactions: Realistic Implications for Best Practice in Patient Monitoring. *Medsurg Nurs*. 2016 ;25(2):88-90, 109.
177. Hendrickson JE, Fasano RM. Management of hemolytic transfusion reactions. *Hematology Am Soc Hematol Educ Program*. 2021;2021(1):704-709. <https://doi:10.1182/hematology.2021000308>.
178. Martí-Carvajal AJ, Solà I, González LE, Leon de Gonzalez G, Rodríguez-Malagon N. Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. *Cochrane Database Syst Rev*. 2010 ;2010(6):CD007539. <https://doi:10.1002/14651858.CD007539.pub2>.
179. Larsen R, Sandhu N, Heegaard NHH, Ullum H, von Stemmann JH, Sørensen E, et al. Changes in circulating inflammatory markers following febrile non-haemolytic transfusion reactions to leucoreduced red cells. *Vox Sang*. 2018 ;113(1):76-79. <https://doi:10.1111/vox.12607>.
180. Wang H, Ren D, Sun H, Liu J. Research progress on febrile non-hemolytic transfusion reaction: a narrative review. *Ann Transl Med*. 2022;10(24):1401. <https://doi:10.21037/atm-22-4932>.
181. Yanagisawa R, Tatsuzawa Y, Ono T, Kobayashi J, Tokutake Y, Hidaka E, et al. Analysis of clinical presentations of allergic transfusion reactions and febrile non-haemolytic transfusion reactions in paediatric patients. *Vox Sang*. 2019;114(8):826-834. <https://doi:10.1111/vox.12833>.
182. Tung JP, Chiaretti S, Dean MM, Sultana AJ, Reade MC, Fung YL. Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions. *Blood Rev*. 2022 ;53:100926. <https://doi:10.1016/j.blre.2021.100926>.
183. Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload and transfusion-related acute lung injury. *Blood*. 2019;133(17):1840-1853. <https://doi:10.1182/blood-2018-10-860809>.
184. Yan CL, Costa PA, Wu Y. Acute pancreatitis from a delayed haemolytic transfusion reaction. *Transfus Med*. 2022 ;32(6):522-524. <https://doi:10.1111/tme.12912>.
185. Rossi M, Pirenne F, Le Roux E, Smaïne D, Belloy M, Eyssette-Guerreau S, et al. Delayed haemolytic transfusion reaction in paediatric patients with sickle cell disease: A retrospective study in a French national reference centre. *Br J Haematol*. 2023;201(1):125-132. <https://doi:10.1111/bjh.18605>.
186. Deb J, Kaur D, Sil S, Bava D, Mohan KA, Jain A, et al. Delayed haemolytic transfusion reaction due to Kidd antibodies. *Transfus Clin Biol*. 2022;29(3):269-272. <https://doi:10.1016/j.tracbi.2022.03.001>.
187. Socie G, Michonneau D. Milestones in acute GVHD pathophysiology. *Front Immunol*. 2022; 13:1079708. <https://doi:10.3389/fimmu.2022.1079708>.
188. Anderson K. Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components. *Transfusion*. 2003;43(12):1652-4. <https://doi:10.1111/j.0041-1132.2003.00631.x>.
189. Rosenberg N, Dardik R. Post-transfusion purpura—when and why? *Isr Med Assoc J*. 2006;8(10):709-10.
190. Waheed U, Arshad M, Saeed M, Wazeer A, Farooq A, Arshad A, et al. Spectrum of alloimmunization among multitransfused beta-thalassemia major patients. *Glob J Transfus Med*. 2019;4(1):39-44. https://doi:10.4103/GJTM.GJTM_52_18.
191. Castleman JS, Kilby MD. Red cell alloimmunization: A 2020 update. *Prenat Diagn*. 2020;40(9):1099-1108. <https://doi:10.1002/pd.5674>.
192. Hendrickson JE, Tormey CA, Shaz BH. Red blood cell alloimmunization mitigation strategies. *Transfus Med Rev*. 2014;28(3):137-44. <https://doi:10.1016/j.tmr.2014.04.008>.
193. Ramirez-Arcos S, Garcia-Otalora M, McDonald C; ISBT Transfusion-Transmitted Infectious Diseases Working Party, Subgroup on Bacteria. Microbiological environmental contamination in the blood supply chain: An international survey by the bacterial subgroup of the ISBT Transfusion-Transmitted Infectious Diseases Working Party. *Vox Sang*. 2023;118(8):656-665. <https://doi:10.1111/vox.13476>.
194. Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman JL. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. *Hematology Am Soc Hematol Educ Program*. 2003:575-89. <https://doi:10.1182/asheducation-2003.1.575>.
195. Heroes AS, Ndalingosu N, Kalema J, Luyindula A, Kashitu D, Akele C, et al. Bacterial contamination of blood products for transfusion in the Democratic Republic of the Congo: temperature monitoring, qualitative and semi-quantitative culture. *Blood Transfus*. 2020;18(5):348-358. <https://doi:10.2450/2020.0108-20>.
196. Klausen SS, Hervig T, Seghatchian J, Reikvam H. Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients. *Transfus Apher Sci*. 2014 ;51(2):97-102. <https://doi:10.1016/j.transci.2014.08.007>.
197. Ahmad Y, Heroes AS, Hume HA, Farouk M, Owusu-Ofori A, Gehrie EA, et al. Bacterial contamination of blood products in Africa. *Transfusion*. 2021;61(3):767-780. <https://doi:10.1111/trf.16262>.
198. Henneman EA, Andrzejewski C Jr, Gawlinski A, McAfee K, Panaccione T, Ziel K. Transfusion-Associated Circulatory Overload: Evidence-Based Strategies to Prevent, Identify, and Manage a Serious Adverse Event. *Crit Care Nurse*. 2017 ;37(5):58-65. <https://doi:10.4037/ccn2017770>.
199. Roubinian N. TACO and TRALI: biology, risk factors, and prevention strategies. *Hematology Am Soc Hematol Educ Program*. 2018 ;2018(1):585-594. <https://doi:10.1182/asheducation-2018.1.585>.
200. Soliman AT, De Sanctis V, Yassin M, Alshurafa A, Ata F, Nashwan A. Blood transfusion and iron overload in patients with Sickle Cell Disease (SCD): Personal experience and a short update of diabetes mellitus occurrence. *Acta Biomed*. 2022;93(4):e2022291. <https://doi:10.23750/abm.v93i4.13330>.
201. Tang AY, Zhou M, Maillis AN, Lai KW, Lane PA, Snyder AB. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019. *Pediatr Blood Cancer*. 2023 ;70(3):e30152. <https://doi:10.1002/pbc.30152>.
202. Saliba A, Taher A. Iron overload in transfusion-dependent thalassemia. *Hematology*. 2015;20(5):311-2. <https://doi:10.1179/1024533215Z.000000000365>.
203. Gattermann N. Iron overload in myelodysplastic syndromes (MDS). *Int J Hematol*. 2018;107(1):55-63. <https://doi:10.1007/s12185-017-2367-1>.

204. Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. *Blood*. 2019;133(17):1831-1839. <https://doi:10.1182/blood-2018-10-833988>.
205. Asadov C, Alimirzoeva Z, Mammadova T, Aliyeva G, Gafarova S, Mammadov J. β -Thalassemia intermedia: a comprehensive overview and novel approaches. *Int J Hematol*. 2018;108(1):5-21. <https://doi:10.1007/s12185-018-2411-9>.
206. Al-Riyami AZ, Daar S. Transfusion in Haemoglobinopathies: Review and recommendations for local blood banks and transfusion services in Oman. *Sultan Qaboos Univ Med J*. 2018;18(1):e3-e12. <https://doi:10.18295/squmj.2018.18.01.002>.
207. Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. *Dtsch Arztebl Int*. 2011;108(31-32):532-40. <https://doi:10.3238/arztebl.2011.0532>.
208. Boudreaux J. Transfusion management in thalassemia. *Ann N Y Acad Sci*. 2023;1527(1):42-48. <https://doi:10.1111/nyas.15049>.
209. Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, et al. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. *Lancet Haematol*. 2023;10(8):e633-e686. [https://doi:10.1016/S23523026\(23\)00096-0](https://doi:10.1016/S23523026(23)00096-0).
210. Seebach JD, Stussi G, Passweg JR, Loberiza FR Jr, Gajewski JL, et al; GVHD Working Committee of Center for International Blood and Marrow Transplant Research. ABO blood group barrier in allogeneic bone marrow transplantation revisited. *Biol Blood Marrow Transplant*. 2005;11(12):1006-13. <https://doi:10.1016/j.bbmt.2005.07.015>.
211. Nemunaitis J, Rosenfeld C, Collins R, Pallansch P, Piñeiro L, Ohr S, et al. Allogeneic transplantation combining mobilized blood and bone marrow in patients with refractory hematologic malignancies. *Transfusion*. 1995;35(8):666-73. <https://doi:10.1046/j.1537-2995.1995.35895357898.x>.
212. Giraud C, Thibert JB, Desbrosses Y, Debiol B, Alsuliman T, Bardiaux L, et al. Transfusion in autologous and allogeneic hematopoietic stem cell transplant: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). *Bull Cancer*. 2019;106(15):S52-S58. French. <https://doi:10.1016/j.bulcan.2018.08.016>.
213. Haspel RL, McKenna DH. Major incompatible red blood cell transfusions prior to bone marrow transplantation: Not worth the risk. *Br J Haematol*. 2023;203(5):889-890. <https://doi:10.1111/bjh.19101>.
214. Okello CD, Orem J, Nabwana M, Kiwanuka N, Shih AW, Heddle N, et al. A randomized control trial to compare mortality in recipients of leucoreduced and non-leucoreduced whole blood transfusion in patients with cancer in Uganda. *BMC Cancer*. 2024;24(1):677. <https://doi:10.1186/s12885-02412445-w>.
215. Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force. *Transfus Med*. 1998;8(1):59-71.
216. Shukla GS, Pero SC, Mei L, Hitchcox S, Fung M, Sprague J, Krag DN. Preparation of clinical-grade WBCs using leukocyte reduction filters. *J Immunol Methods*. 2021;499:113157. <https://doi:10.1016/j.jim.2021.113157>.
217. Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. *Transfusion*. 2002;42(11):1398-413. <https://doi:10.1046/j.1537-2995.2002.00208.x>.
218. Carson JL, Guyatt G, Heddle NM. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. *JAMA*. 2016;316(19):2025-2035. <https://doi:10.1001/jama.2016.9185>.
219. Karam O, Tucci M, Ducruet T, Hume HA, Lacroix J, Gauvin F; Canadian Critical Care Trials Group; PALISI Network. Red blood cell transfusion thresholds in pediatric patients with sepsis. *Pediatr Crit Care Med*. 2011;12(5):512-8. <https://doi:10.1097/PCC.0b013e3181fe344b>.
220. Kirpalani H, Bell EF, Hintz SR, Tan S, Schmidt B, Chaudhary AS, et al; Eunice Kennedy Shriver NICHD Neonatal Research Network. Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants. *N Engl J Med*. 2020;383(27):2639-2651. <https://doi:10.1056/NEJMoa2020248>.
221. Howarth C, Banerjee J, Aladangady N. Red Blood Cell Transfusion in Preterm Infants: Current Evidence and Controversies. *Neonatology*. 2018;114(1):7-16. <https://doi:10.1159/000486584>.
222. Kelly AM, Williamson LM. Neonatal transfusion. *Early Hum Dev*. 2013;89(11):85560. <https://doi:10.1016/j.earlhumdev.2013.08.025>.
223. Crowley M, Kirpalani H. A rational approach to red blood cell transfusion in the neonatal ICU. *Curr Opin Pediatr*. 2010;22(2):151-7. <https://doi:10.1097/MOP.0b013e328336eb3e>.
224. Kumar J, Yadav A, Meena J. Thrombocytopenia following exchange transfusion in neonates. *J Perinatol*. 2020;40(7):1120. <https://doi:10.1038/s41372-020-0683-4>.
225. Aradhya AS, Sundaram V, Kumar P, Ganapathy SM, Jain A, Rawat A. Double Volume Exchange Transfusion in Severe Neonatal Sepsis. *Indian J Pediatr*. 2016;83(2):107-13. <https://doi:10.1007/s12098-015-1841-0>.
226. Mathias S, Balachander B, Bosco A, Britto C, Rao S. The effect of exchange transfusion on mortality in neonatal sepsis: a meta-analysis. *Eur J Pediatr*. 2022;181(1):369-381. <https://doi:10.1007/s00431-021-04194-w>.
227. Pagni L, Ronchi A, Bizzarri B, Consonni D, Pietrasanta C, Ghirardi B, et al. Exchange Transfusion in the Treatment of Neonatal Septic Shock: A Ten-Year Experience in a Neonatal Intensive Care Unit. *Int J Mol Sci*. 2016;17(5):695. <https://doi:10.3390/ijms17050695>.
228. Han H, Hensch L, Tubman VN. Indications for transfusion in the management of sickle cell disease. *Hematology Am Soc Hematol Educ Program*. 2021;2021(1):696-703. <https://doi:10.1182/hematology.2021000307>.
229. Viridi VS, Goraya JS, Khadwal A, Seth A. Neonatal transfusion malaria requiring exchange transfusion. *Ann Trop Paediatr*. 2003;23(3):205-7. <https://doi:10.1179/027249303322296529>.
230. Shanbag P, Juvekar M, More V, Vaidya M. Exchange transfusion in children with severe falciparum malaria and heavy parasitaemia. *Ann Trop Paediatr*. 2006;26(3):199-204. <https://doi:10.1179/146532806X120282>.
231. Schonewille H, Klumper FJ, van de Watering LM, Kanhai HH, Brand A. High additional maternal red cell alloimmunization after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus. *Am J Obstet Gynecol*. 2007;196(2):143.e1-6. <https://doi:10.1016/j.ajog.2006.10.895>.
232. Walsh CA, Russell N, McAuliffe FM, Higgins S, Mahony R, Carroll S, et al. Relationship between maternal antibody type and antenatal course following intrauterine transfusion for

- red cell alloimmunisation. *Eur J Obstet Gynecol Reprod Biol.* 2013;171(2):235-9. <https://doi:10.1016/j.ejogrb.2013.09.002>.
233. Bosboom JJ, Klanderman RB, Terwindt LE, Bulle EB, Wijnberge M, Eberl S, et al. Autologous red blood cell transfusion does not result in a more profound increase in pulmonary capillary wedge pressure compared to saline in critically ill patients: A randomized crossover trial. *Vox Sang.* 2022;117(8):1035-1042. <https://doi:10.1111/vox.13292>.
 234. Berra L, Pincioli R, Stowell CP, Wang L, Yu B, Fernandez BO, et al. Autologous transfusion of stored red blood cells increases pulmonary artery pressure. *Am J Respir Crit Care Med.* 2014;190(7):800-7. <https://doi:10.1164/rccm.201405-0850O>.
 235. Pawaskar A, Salunke AA, Kekatpure A, Chen Y, Nambi GI, Tan J, et al. Do autologous blood transfusion systems reduce allogeneic blood transfusion in total knee arthroplasty? *Knee Surg Sports Traumatol Arthrosc.* 2017;25(9):2957-2966. <https://doi:10.1007/s00167-016-4116-z>.
 236. Carless P, Moxey A, O'Connell D, Henry D. Autologous transfusion techniques: a systematic review of their efficacy. *Transfus Med.* 2004;14(2):123-44. <https://doi:10.1111/j.0958-7578.2004.0489.x>.
 237. van der Meer PF, de Korte D. The effect of holding times of whole blood and its components during processing on in vitro and in vivo quality. *Transfus Med Rev.* 2015;29(1):24-34. <https://doi:10.1016/j.tmr.2014.10.001>.
 238. Moroff G, AuBuchon JP, Pickard C, Whitley PH, Heaton WA, Holme S. Evaluation of the properties of components prepared and stored after holding of whole blood units for 8 and 24 hours at ambient temperature. *Transfusion.* 2011;51 Suppl 1:7S-14S. <https://doi:10.1111/j.1537-2995.2010.02958.x>.
 239. Isbister J. Why should health professionals be concerned about blood management and blood conservation? *Updates in Blood Conservation and Transfusion Alternatives.* 2005;2:3-7.
 240. Isbister J. The three-pillar matrix of patient blood management. *ISBT Sci Ser* 2015;10(S1):286-294. <https://doi:10.1111/vox.12135>.
 241. Franchini M, Marano G, Veropalumbo E, Masiello F, Pati I, Candura F, et al. Patient Blood Management: a revolutionary approach to transfusion medicine. *Blood Transfus.* 2019;17(3):191-195. <https://doi:10.2450/2019.0109-19>.
 242. Markowitz MA, Waters JH, Ness PM. Patient blood management: a primary theme in transfusion medicine. *Transfusion.* 2014;54(10 Pt 2):2587. <https://doi:10.1111/trf.12862>.
 243. Bolcato M, Russo M, Trentino K, Isbister J, Rodriguez D, Aprile A. Patient blood management: The best approach to transfusion medicine risk management. *Transfus Apher Sci.* 2020;59(4):102779. <https://doi:10.1016/j.transci.2020.102779>.
 244. Goobie SM, Gallagher T, Gross I, Shander A. Society for the advancement of blood management administrative and clinical standards for patient blood management programs. 4th edition (pediatric version). *Paediatr Anaesth.* 2019;29(3):231-236. <https://doi:10.1111/pan.13574>.
 245. Kazamer A, Ilinca R, Stanescu-Spinu II, Lutescu DA, Greabu M, Miricescu D, et al. Perceptions of the Conditions and Barriers in Implementing the Patient Blood Management Standard by Anesthesiologists and Surgeons. *Healthcare (Basel).* 2024;12(7):760. <https://doi:10.3390/healthcare12070760>.
 246. Meybohm P, Hof L, Choorapoikayil S, Zacharowski K. Patient blood management: We still have work to do. *Transfus Med Hemother.* 2023;50(6):561-563. <https://doi:10.1159/000534087>.
 247. World Health Organization. Policy Brief 2021. The urgent need to implement patient blood management [Internet]. Available from: <https://apps.who.int/iris/bitstream/handle/10665/346655/9789240035744-eng.pdf>. [cited 2024 Nov 4]. ISBN: 9789240035744.